Cover Page
Cover Page - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Feb. 14, 2024 | Jun. 30, 2023 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 0-12015 | ||
Entity Registrant Name | HEALTHCARE SERVICES GROUP, INC. | ||
Entity Incorporation, State Code | PA | ||
I.R.S. Employer Identification No. | 23-2018365 | ||
Entity Address, Address Line One | 3220 Tillman Drive | ||
Entity Address, Address Line Two | Suite 300 | ||
Entity Address, City or Town | Bensalem | ||
Entity Address, State or Province | PA | ||
Entity Address, Postal Zip Code | 19020 | ||
City Area Code | 215 | ||
Local Phone Number | 639-4274 | ||
Title of 12(b) Security | Common Stock, $0.01 par value | ||
Trading Symbol | HCSG | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Document Financial Statement Error Correction | true | ||
Document Financial Statement Restatement Recovery Analysis | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 907 | ||
Entity Common Stock, Shares Outstanding | 73,583,055 | ||
Documents Incorporated by Reference | Portions of the definitive Proxy Statement for the Registrant’s Annual Meeting of Shareholders to be held on May 28, 2024 have been incorporated by reference into Parts II and III of this Annual Report on Form 10-K. | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Entity Central Index Key | 0000731012 |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2023 | |
Auditor Information [Abstract] | |
Auditor Name | GRANT THORNTON LLP |
Auditor Location | Philadelphia, Pennsylvania |
Auditor Firm ID | 248 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 54,330 | $ 26,279 |
Marketable securities, at fair value | 93,131 | 95,200 |
Accounts and notes receivable, less allowance for doubtful accounts of $87,250 and $70,192 as of December 31, 2023 and 2022, respectively | 383,509 | 336,777 |
Inventories and supplies | 18,479 | 21,164 |
Taxes receivable | 0 | 6,629 |
Prepaid expenses and other assets | 22,247 | 22,583 |
Total current assets | 571,696 | 508,632 |
Property and equipment, net | 28,774 | 22,975 |
Goodwill | 75,529 | 75,529 |
Other intangible assets, less accumulated amortization of $36,557 and $32,738 as of December 31, 2023 and 2022, respectively | 12,127 | 15,946 |
Notes receivable — long–term portion, less allowance for doubtful accounts of $4,449 and $3,273 as of December 31, 2023 and 2022, respectively | 24,832 | 32,609 |
Deferred compensation funding, at fair value | 40,812 | 33,493 |
Deferred tax assets | 35,226 | 30,840 |
Other long-term assets | 1,656 | 812 |
Total assets | 790,652 | 720,836 |
Current liabilities: | ||
Accounts payable | 83,224 | 68,296 |
Accrued payroll and related taxes | 56,142 | 53,099 |
Other accrued expenses and current liabilities | 21,179 | 17,835 |
Borrowings under line of credit | 25,000 | 25,000 |
Income taxes payable | 7,201 | 0 |
Deferred compensation liability — short-term | 1,501 | 1,618 |
Accrued insurance claims | 22,681 | 23,166 |
Total current liabilities | 216,928 | 189,014 |
Accrued insurance claims — long-term | 61,697 | 65,541 |
Deferred compensation liability — long-term | 41,186 | 33,764 |
Lease liability — long-term | 11,235 | 8,097 |
Other long-term liabilities | 2,990 | 6,141 |
Commitments and contingencies (Note 15) | ||
STOCKHOLDERS’ EQUITY: | ||
Common stock, $0.01 par value; 100,000 shares authorized; 76,329 and 76,161 shares issued, and 73,341 and 74,088 shares outstanding as of December 31, 2023 and 2022, respectively | 763 | 762 |
Additional paid-in capital | 310,436 | 302,304 |
Retained earnings | 185,010 | 146,602 |
Accumulated other comprehensive loss, net of taxes | (1,844) | (3,477) |
Common stock in treasury, at cost, 2,988 and 2,240 shares as of December 31, 2023 and 2022, respectively | (37,749) | (27,912) |
Total stockholders’ equity | 456,616 | 418,279 |
Total liabilities and stockholders’ equity | $ 790,652 | $ 720,836 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts, current | $ 87,250 | $ 70,192 |
Accumulated amortization of other intangible assets | 36,557 | 32,738 |
Allowance for doubtful accounts, noncurrent | $ 4,449 | $ 3,273 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock issued (in shares) | 76,329,000 | 76,161,000 |
Common stock outstanding (in shares) | 73,341,000 | 74,088,000 |
Common stock in treasury (in shares) | 2,988,000 | 2,240,000 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Revenues | $ 1,671,389 | $ 1,690,176 | $ 1,641,959 |
Operating costs and expenses: | |||
Costs of services provided | 1,456,643 | 1,496,865 | 1,411,393 |
Selling, general and administrative expense | 166,772 | 140,344 | 173,108 |
Other income (expense): | |||
Investment and other income (loss), net | 12,938 | (5,427) | 9,439 |
Interest expense | (7,856) | (2,987) | (1,385) |
Income before income taxes | 53,056 | 44,553 | 65,512 |
Income tax provision | 14,670 | 10,310 | 16,969 |
Net income | $ 38,386 | $ 34,243 | $ 48,543 |
Per share data: | |||
Basic earnings per common share (in dollars per share) | $ 0.52 | $ 0.46 | $ 0.65 |
Diluted earnings per common share (in dollars per share) | $ 0.52 | $ 0.46 | $ 0.65 |
Weighted average number of common shares outstanding: | |||
Basic (in shares) | 74,288 | 74,336 | 74,816 |
Diluted (in shares) | 74,340 | 74,351 | 74,962 |
Comprehensive income: | |||
Net income | $ 38,386 | $ 34,243 | $ 48,543 |
Other comprehensive income (loss): | |||
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes | 1,633 | (7,477) | (1,563) |
Total comprehensive income | $ 40,019 | $ 26,766 | $ 46,980 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Cash flows from operating activities: | |||
Net income | $ 38,386 | $ 34,243 | $ 48,543 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||
Depreciation and amortization | 14,344 | 15,316 | 14,667 |
Bad debt provision | 35,604 | 31,969 | 10,483 |
Deferred income tax (benefit) expense | (4,820) | 4,907 | 4,083 |
Share-based compensation expense | 8,985 | 9,214 | 8,827 |
Amortization of premium on marketable securities | 2,144 | 2,219 | 2,275 |
Unrealized (gain) loss on deferred compensation fund investments | (6,645) | 9,422 | (6,397) |
Changes in fair value of other long-term liabilities | (1,154) | (2,353) | 0 |
Net loss on disposals of property and equipment | 818 | 1,138 | 1,469 |
Changes in operating assets and liabilities: | |||
Accounts and notes receivable | (74,559) | (78,707) | (37,185) |
Inventories and supplies | 2,685 | 4,851 | 5,599 |
Prepaid expenses and other assets | 12,750 | 9,935 | (12,250) |
Deferred compensation funding, net | (674) | 3,913 | 6,661 |
Accounts payable and other accrued expenses | 7,430 | (13,748) | 10,244 |
Accrued payroll, accrued and withheld payroll taxes | 4,186 | (23,859) | (25,878) |
Income taxes receivable and payable | 572 | 2,184 | (8,420) |
Accrued insurance claims | (4,329) | (687) | 6,966 |
Deferred compensation liability | 7,775 | (18,124) | 7,421 |
Net cash provided by (used in) operating activities | 43,498 | (8,167) | 37,108 |
Cash flows (used in) from investing activities: | |||
Disposals of property and equipment | 121 | 393 | 211 |
Additions to property and equipment | (5,406) | (5,210) | (5,687) |
Purchases of marketable securities | 0 | (2,875) | (20,335) |
Sales of marketable securities | 1,992 | 10,386 | 26,697 |
Cash paid for acquisitions | 0 | (114) | (23,876) |
Net cash (used in) provided by investing activities | (3,293) | 2,580 | (22,990) |
Cash flows used in financing activities: | |||
Dividends paid | 0 | (63,373) | (62,226) |
Reissuance of treasury stock pursuant to Dividend Reinvestment Plan | 0 | 106 | 92 |
Proceeds from the exercise of stock options | 0 | 410 | 2,425 |
Purchases of treasury stock | (11,283) | 0 | (21,535) |
Short-term borrowings, net of repayments | 0 | 25,000 | 0 |
Payments of statutory withholding on net issuance of restricted stock units | (871) | (1,071) | (1,410) |
Net cash used in financing activities | (12,154) | (38,928) | (82,654) |
Net change in cash and cash equivalents | 28,051 | (44,515) | (68,536) |
Cash and cash equivalents at beginning of the period | 26,279 | 70,794 | 139,330 |
Cash and cash equivalents at end of the period | 54,330 | 26,279 | 70,794 |
Supplementary cash flow information: | |||
Cash paid for interest | 7,809 | 2,822 | 1,385 |
Cash paid for income taxes | 5,585 | 3,309 | 21,233 |
Accrued variable consideration for acquisition of businesses | $ 0 | $ 0 | $ 10,456 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Income (Loss), net of Taxes | Retained Earnings | Treasury Stock |
Beginning balance (in shares) at Dec. 31, 2020 | 75,798 | |||||
Beginning balance at Dec. 31, 2020 | $ 470,276 | $ 758 | $ 282,206 | $ 5,563 | $ 190,708 | $ (8,959) |
Comprehensive income: | ||||||
Net income for the period | 48,543 | 48,543 | ||||
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes | (1,563) | (1,563) | ||||
Total comprehensive income | 46,980 | |||||
Exercise of stock options and other stock-based compensation, net of shares tendered for payment (in shares) | 207 | |||||
Exercise of stock options and other share-based compensation, net of shares tendered for payment | 2,425 | $ 2 | 2,423 | |||
Payment of statutory withholding on issuance of restricted stock units | (1,410) | (1,410) | ||||
Share-based compensation expense | 8,600 | 8,600 | ||||
Purchases of treasury stock | (21,535) | (21,535) | ||||
Treasury shares issued for Deferred Compensation Plan funding, net | 368 | 574 | (206) | |||
Shares issued pursuant to Employee Stock Plan | 2,052 | 1,554 | 498 | |||
Dividends paid and accrued | (62,800) | (62,800) | ||||
Shares issued pursuant to Dividend Reinvestment Plan | 92 | 54 | 38 | |||
Other (in shares) | 4 | |||||
Other | 123 | 123 | ||||
Ending balance (in shares) at Dec. 31, 2021 | 76,009 | |||||
Ending balance at Dec. 31, 2021 | 445,171 | $ 760 | 294,124 | 4,000 | 176,451 | (30,164) |
Comprehensive income: | ||||||
Net income for the period | 34,243 | 34,243 | ||||
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes | (7,477) | (7,477) | ||||
Total comprehensive income | 26,766 | |||||
Exercise of stock options and other stock-based compensation, net of shares tendered for payment (in shares) | 148 | |||||
Exercise of stock options and other share-based compensation, net of shares tendered for payment | 410 | $ 2 | 408 | |||
Payment of statutory withholding on issuance of restricted stock units | (1,071) | (1,071) | ||||
Share-based compensation expense | 9,044 | 9,044 | ||||
Purchases of treasury stock | 0 | |||||
Treasury shares issued for Deferred Compensation Plan funding, net | 374 | (634) | 1,008 | |||
Shares issued pursuant to Employee Stock Plan | 1,512 | 368 | 1,144 | |||
Dividends paid and accrued | (64,092) | (64,092) | ||||
Shares issued pursuant to Dividend Reinvestment Plan | 106 | 6 | 100 | |||
Other (in shares) | 4 | |||||
Other | $ 59 | 59 | ||||
Ending balance (in shares) at Dec. 31, 2022 | 74,088 | 76,161 | ||||
Ending balance at Dec. 31, 2022 | $ 418,279 | $ 762 | 302,304 | (3,477) | 146,602 | (27,912) |
Comprehensive income: | ||||||
Net income for the period | 38,386 | 38,386 | ||||
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes | 1,633 | 1,633 | ||||
Total comprehensive income | 40,019 | |||||
Exercise of stock options and other stock-based compensation, net of shares tendered for payment (in shares) | 167 | |||||
Exercise of stock options and other share-based compensation, net of shares tendered for payment | 0 | $ 1 | (1) | |||
Payment of statutory withholding on issuance of restricted stock units | (870) | (870) | ||||
Share-based compensation expense | 8,836 | 8,836 | ||||
Purchases of treasury stock | (11,283) | (11,283) | ||||
Treasury shares issued for Deferred Compensation Plan funding, net | 470 | 298 | 172 | |||
Shares issued pursuant to Employee Stock Plan | 1,135 | (139) | 1,274 | |||
Other (in shares) | 1 | |||||
Other | $ 30 | 8 | 22 | |||
Ending balance (in shares) at Dec. 31, 2023 | 73,341 | 76,329 | ||||
Ending balance at Dec. 31, 2023 | $ 456,616 | $ 763 | $ 310,436 | $ (1,844) | $ 185,010 | $ (37,749) |
Consolidated Statements of St_2
Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Statement of Stockholders' Equity [Abstract] | ||
Cash dividend paid per common share (in dollars per share) | $ 0.86 | $ 0.84 |
Description of Business and Sig
Description of Business and Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Description of Business and Significant Accounting Policies | Note 1 — Description of Business and Significant Accounting Policies Nature of Operations Healthcare Services Group, Inc. (the “Company”) provides management, administrative and operating expertise and services to the housekeeping, laundry, linen, facility maintenance and dietary service departments of the healthcare industry, including nursing homes, retirement complexes, rehabilitation centers and hospitals located throughout the United States. Although the Company does not directly participate in any government reimbursement programs, the Company’s customers receive government reimbursements related to Medicare and Medicaid. Therefore, they are directly affected by any legislation relating to Medicare and Medicaid reimbursement programs. The Company provides services primarily pursuant to full service agreements with its customers. In such agreements, the Company is responsible for the day-to-day management of employees located at the customers’ facilities, as well as for the provision of certain supplies. The Company also provides services on the basis of management-only agreements for a limited number of customers. In a management-only agreement, the Company provides management and supervisory services while the customer facility retains payroll responsibility for the non-supervisory staff. The agreements with customers typically provide for a renewable one year service term, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days. The Company is organized into two reportable segments: housekeeping, laundry, linen and other services (“Housekeeping”), and dietary department services (“Dietary”). Housekeeping consists of managing the customers’ housekeeping departments, which are principally responsible for the cleaning, disinfecting and sanitizing of resident rooms and common areas of a customer’s facility, as well as the laundering and processing of the bed linens, uniforms, resident personal clothing and other assorted linen items utilized at a customer facility. Dietary consists of managing the customers’ dietary departments, which are principally responsible for food purchasing, meal preparation and dietitian professional services, which includes the development of menus that meet residents’ dietary needs. Principles of Consolidation The financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the SEC, specifically Regulation S-X and the instructions to Form 10-K. Unless otherwise indicated, all references to years are to the Company’s fiscal year, which ends on December 31. The accompanying Consolidated Financial Statements include the accounts of Healthcare Services Group, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Use of Estimates in Financial Statements In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes. Fair Value of Financial Instruments The Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3) within the fair value hierarchy. Assets and liabilities are classified within the fair value hierarchy based on the lowest level (least observable) input that is significant to the measurement in its entirety. While unobservable inputs reflect the Company’s market assumptions, preference is given to observable inputs. These two types of inputs create the following fair value hierarchy: Level 1 – Quoted prices for identical instruments in active markets; Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable; and Level 3 – Significant inputs to the valuation model are unobservable The Company’s financial instruments that are measured at fair value on a recurring basis consist of marketable securities and the deferred compensation fund investments. The carrying value of other financial instruments such as cash and cash equivalents, accounts and short-term notes receivable, accounts payable (including income taxes payable and accrued expenses) and borrowings under the Company’s line of credit approximate their fair values at December 31, 2023 and 2022, due to the short period of time to maturity or repayment. Cash and Cash Equivalents Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as short-term, highly liquid investments with a maturity of three months or less at time of purchase that are readily convertible into cash and have insignificant interest rate risk. The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. Investments in Marketable Securities Marketable securities are defined as fixed income investments which are highly liquid and can be readily purchased or sold through established markets. As of December 31, 2023 and 2022, the Company had marketable securities of $93.1 million and $95.2 million, respectively, comprised primarily of tax-exempt municipal bonds. These investments are accounted for as available-for-sale securities and are reported at fair value on the Company's Consolidated Balance Sheets. For the year ended December 31, 2023, $1.6 million of unrealized gains related to these investments were recorded in Other comprehensive income (loss). For the years ended December 31, 2022 and 2021, $7.5 million and $1.6 million of unrealized losses related to these marketable securities were recorded in Other comprehensive income (loss), respectively. Unrealized gains and losses are recorded net of income taxes. These assets are held by the Company’s wholly-owned captive insurance company subsidiary as required by state insurance regulations. The Company’s investment policy is intended to manage the assets to achieve the goals of preserving principal, maintaining adequate liquidity at all times and maximizing returns subject to investment guidelines. The investment policy limits investment to certain types of instruments issued by institutions primarily with investment grade credit ratings and places restrictions on concentration by type and issuer. The Company periodically reviews the investments in marketable securities for credit impairment when an investment’s fair value declines below the amortized cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. As of December 31, 2023, management believes that the recorded value of the Company’s investments in marketable securities was recoverable in all material respects. Accounts and Notes Receivable Accounts and notes receivable consist of Housekeeping and Dietary segment trade receivables from contracts with customers. The Company’s payment terms with customers for services provided are defined within each customer’s service agreement and range from prepaid to 120 days. Accounts receivable are considered short term assets as the Company does not grant payment terms greater than one year. Accounts receivable initially are recorded at the transaction amount and are recorded after the Company has an unconditional right to payment where only the passage of time is required before payment is received. Each reporting period, the Company evaluates the collectability of outstanding receivable balances and records an allowance for doubtful accounts representing an estimate of current expected credit loss. Additions to the allowance for doubtful accounts are made by recording a charge to bad debt expense reported in costs of services provided. Notes receivable are initially recorded when accounts receivable are transferred into a promissory note and are recorded as an alternative to accounts receivable to memorialize an unqualified promise to pay a specific sum, typically with interest, in accordance with a defined payment schedule. The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however typically promissory notes mature over a 1 to 4 year period. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses. Allowance for Doubtful Accounts Management utilizes financial modeling to determine an allowance that reflects its best estimate of the lifetime expected credit losses on accounts and notes receivable which is recorded to offset the receivables. Modeling is prepared after considering historical experience, current conditions, and reasonable and supportable economic forecasts to estimate lifetime expected credit losses. Accounts and notes receivable are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded as a reduction of bad debt expense when received. Inventories and Supplies Inventories and supplies include housekeeping, linen and laundry supplies, as well as food provisions and supplies. Non-linen inventories and supplies are stated on a first-in, first-out (FIFO) basis, and reduced as deemed necessary to approximate the lower of cost or net realizable value. Linen supplies are amortized on a straight-line basis over their estimated useful life of 24 months. Revenue Recognition The Company recognizes revenue from contracts with customers when or as the promised goods and services are provided to customers. Revenues are reported net of sales taxes that are collected from customers and remitted to taxing authorities. The amount of revenue recognized by the Company is based on the consideration to which the Company is entitled in exchange for providing the contracted goods and services and when it is probable that the Company will collect substantially all of such consideration. Leases The Company records assets and liabilities on the Consolidated Balance Sheets to recognize the rights and obligations arising from leasing arrangements with contractual terms greater than 12 months. A leasing arrangement includes any contract which entitles the Company to the right of use of an identified tangible asset where there are no restrictions as to the direct of use of the asset, and the Company obtains substantially all of the economic benefits from the right of use. Property and Equipment, Net Property and equipment, with the exception of those pertaining to leases, are stated at cost, net of accumulated depreciation. Additions, renewals and improvements are capitalized, while maintenance and repair costs are expensed when incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is included in Investment and other income (loss), net on the Consolidated Statements of Comprehensive Income. Depreciation is recorded using the straight-line method over the following estimated useful lives: Housekeeping and Dietary equipment — 3 to 5 years; computer hardware and software — 5 years; and other, consisting of furniture and fixtures, leasehold improvements and vehicles — 5 to 10 years. Depreciation expense on property and equipment, inclusive of amortization of lease right-of-use assets, for the years ended December 31, 2023, 2022 and 2021 was $10.5 million, $10.5 million and $10.3 million, respectively. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, income tax expense or benefits are recognized for the amount of taxes payable or refundable for the current period. The Company accrues for probable tax obligations as required based on facts and circumstances in various regulatory environments. In addition, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. When appropriate, valuation allowances are recorded to reduce deferred tax assets to amounts for which realization is more likely than not. Uncertain income tax positions taken or expected to be taken in tax returns are reflected within the Company’s Consolidated Financial Statements based on a recognition and measurement process. The Company may from time to time be assessed interest or penalties by taxing jurisdictions, although any such assessments historically have been minimal and immaterial to its financial results. When the Company has received an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense. In addition, any interest or penalties relating to recognized uncertain tax positions would also be recorded in selling, general and administrative expense. Earnings per Common Share Basic earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per common share is computed using the weighted-average number of common shares outstanding and dilutive common shares, such as those issuable upon exercise of stock options and upon the vesting of restricted stock and restricted stock units. Share-Based Compensation The Company estimates the fair value of share-based awards on the date of grant using the Black-Scholes valuation model for stock options, using a Monte Carlo simulation for performance restricted stock units and using the share price on the date of grant for restricted stock units and deferred stock units. The value of the award is recognized ratably as an expense in the Company’s Consolidated Statements of Comprehensive Income over the requisite service periods, with adjustments made for forfeitures as they occur. Advertising Costs Advertising costs are expensed when incurred. Advertising costs were not material for the years ended December 31, 2023, 2022 and 2021. Impairment of Long-Lived Assets The carrying amounts of long-lived assets are periodically reviewed to determine whether current events or circumstances warrant adjustment to such carrying amounts. Any impairment would be measured as the amount that the carrying value of such assets exceeds their fair value. Considerable management judgment is necessary to estimate the fair value of assets. Assets to be disposed of are carried at the lower of their financial statement carrying amount or fair value, less cost to sell. No impairment loss was recognized on the Company’s long-lived assets during the years ended December 31, 2023, 2022 or 2021. Identifiable Intangible Assets and Goodwill Identifiable intangible assets are amortized on a straight-line basis over their respective lives. Goodwill represents the excess of cost over the fair value of net assets of acquired businesses. Management reviews the carrying value of goodwill annually during the fourth quarter to assess for impairment on a reporting unit basis or more often if events or circumstances indicate that the carrying value may exceed its estimated fair value. No impairment loss was recognized on the Company's intangible assets or goodwill during the years ended December 31, 2023, 2022 or 2021. Treasury Stock Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid-in capital. Concentrations of Credit Risk The Company’s financial instruments that are subject to credit risk are cash and cash equivalents, marketable securities, deferred compensation funding and accounts and notes receivable. At December 31, 2023 and 2022, the majority of the Company’s cash and cash equivalents and marketable securities were held in one large financial institution located in the United States. The Company’s marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could directly impact the governmental reimbursement programs in which the customers participate. As a result, the Company may not realize the full effects of such programs until these laws are fully implemented and governmental agencies issue applicable regulations or guidance. Although the Company negotiates the pricing and other terms for the majority of our purchases of food and dining supplies directly with national manufacturers, the Company procures more than 50% of these products and other items through Sysco Corporation (“Sysco”). Sysco is responsible for tracking the Company’s orders and delivering products to the Company’s specific locations. Significant Customer For the years ended December 31, 2023, 2022 and 2021, Genesis Healthcare, Inc. (“Genesis”) accounted for $181.4 million or 10.9%, $169.1 million or 10.0% and $177.1 million or 10.8% of the Company’s consolidated revenues, respectively. As of December 31, 2023, the Company had outstanding accounts receivable and notes receivable of $61.8 million and $20.4 million, respectively, from Genesis. Although the Company expects to continue its relationship with Genesis, there can be no assurance thereof. Revenues generated from Genesis were included in both operating segments previously mentioned. Any extended discontinuance of revenues, or significant reduction, from this customer could, if not replaced, have a material impact on our operations. In addition, if Genesis fails to abide by current payment terms it could increase our accounts receivable balance and have a material adverse effect on our financial condition, results of operations, and cash flows. No other single customer or customer group represented more than 10% of consolidated revenues for the years ended December 31, 2023, 2022 and 2021. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation, including the presentation of deferred taxes in Note 12 — Income Taxes. There was no impact to the Company's consolidated financial statements as a result of this reclassification. Recent Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which enhances effective tax rate reconciliation disclosure requirements and provides clarity to the disclosures of income taxes paid, income before taxes and provision for income taxes. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The amendments in this update should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company’s present or future consolidated financial statements. Employee Retention Credit On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). One provision within the CARES Act provided an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable tax credit against the employer share of Social Security tax equal to 50% of the qualified wages paid to employees from March 13, 2020 through December 31, 2020. The ERC was subsequently expanded in 2021 for employers to claim a refundable tax credit for 70% of the qualified wages paid to employees from January 1, 2021 through September 30, 2021. The Company accounted for the ERC by analogy to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. During the quarter ended June 30, 2023, the Company filed a claim for the ERC for qualified wages paid in 2020 and 2021. Through February 16, 2024, the Company has yet to receive any refunds or receive any correspondence from the IRS regarding the ERC filing. The Company believes that there is not reasonable assurance that any receipt of credits will be obtained and therefore has not recognized any amounts related to the ERC in the accompanying consolidated financial statements. Should reasonable assurance over receipt of and compliance with terms of the ERC credits be obtained in future periods, the Company would recognize such amounts as an offset to expense within “Costs of services provided” in the Consolidated Statements of Comprehensive Income. In the event the Company obtains a refund in future periods, such refunds would be subject to IRS audit under the applicable statute of limitations. |
Revision of Prior Period Financ
Revision of Prior Period Financial Statements | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Changes and Error Corrections [Abstract] | |
Revision of Prior Period Financial Statements | Note 2 — Revision of Prior Period Financial Statements During the current year-end financial reporting process, the Company identified a prior period accounting error related to the Company’s estimate for accrued payroll, and specifically accrued vacation that was concluded to not be material to the Company’s previously reported consolidated financial statements or unaudited interim condensed consolidated financial statements. The Company assessed the quantitative and qualitative factors associated with the foregoing error in accordance with SEC Staff Accounting Bulletin (“SAB”) No. 99 and 108, Materiality, codified in ASC 250, Presentation of Financial Statements, and concluded that the error was not material to any of the Company’s previously reported annual or interim consolidated financial statements. Notwithstanding this conclusion, the Company corrected the errors by revising the consolidated 2022 and 2021 accompanying consolidated financial statements and related notes to give effect to the correction of these errors. The identified error related to the accuracy of the Company’s estimate for accrued payroll, and specifically accrued vacation, which US GAAP provides guidance for within ASC 710 - Compensation. Over the past three years the Company had paid vacation hours, either to current employees or for payouts to terminated employees, and such amounts were recorded to expense in the corresponding payroll periods that the vacation was paid. The effect of the correction of the error noted above on the Company’s Consolidated Balance Sheets as of December 31, 2022 is as follows: December 31, 2022 As reported Adjustment Revised (in thousands) Deferred tax asset $ 28,338 $ 2,502 $ 30,840 Total assets $ 718,334 $ 2,502 $ 720,836 Accrued payroll and related taxes $ 42,704 $ 10,395 $ 53,099 Total current liabilities $ 178,619 $ 10,395 $ 189,014 Retained earnings $ 154,495 $ (7,893) $ 146,602 Total liabilities and stockholders' equity $ 718,334 $ 2,502 $ 720,836 The effect of the correction of the error noted above on the Company’s Consolidated Statements of Comprehensive Income for the year ended December 31, 2022 is as follows: Year ended December 31, 2022 As reported Adjustment Revised (in thousands, except per share amounts) Costs of services provided $ 1,496,336 $ 529 $ 1,496,865 Income before income taxes $ 45,082 $ (529) $ 44,553 Income tax provision $ 10,452 $ (142) $ 10,310 Net income $ 34,630 $ (387) $ 34,243 Basic earnings per common share $ 0.47 $ (0.01) $ 0.46 Diluted earnings per common share $ 0.47 $ (0.01) $ 0.46 The effect of the correction of the errors noted above on the Company’s Consolidated Statements of Comprehensive Income for the year ended December 31, 2021 is as follows: Year ended December 31, 2021 As reported Adjustment Revised (in thousands, except per share amounts) Costs of services provided $ 1,415,082 $ (3,689) $ 1,411,393 Income before income taxes $ 61,823 $ 3,689 $ 65,512 Income tax provision $ 15,960 $ 1,009 $ 16,969 Net income $ 45,863 $ 2,680 $ 48,543 Basic earnings per common share $ 0.61 $ 0.04 $ 0.65 Diluted earnings per common share $ 0.61 $ 0.04 $ 0.65 In addition to the effect of the corrections noted above, the errors also reduced retained earnings by $7.5 million and $10.2 million as of December 31, 2021 and December 31, 2020, respectively, as presented in the Consolidated Statements of Stockholders’ Equity. The effect of the correction of the errors noted above had no impact on the Company’s previously reported consolidated statements of cash flows for the years ended December 31, 2022 or 2021, except for adjustments to individual line items as described in the tables above. The effect of the correction of the errors above on income tax provision for the years ended December 31, 2022 and 2021 and related footnotes is reflected in Note 12 — Income Taxes. |
Revenue
Revenue | 12 Months Ended |
Dec. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Note 3 — Revenue The Company presents its consolidated revenues disaggregated by reportable segment, as Management evaluates the nature, amount, timing and uncertainty of the Company’s revenues by segment. Refer to Note 13 — Segment Information herein as well as the information below regarding the Company’s reportable segments. Housekeeping Housekeeping accounted for $766.7 million, $795.7 million and $821.3 million of the Company’s consolidated revenues for the years ended December 31, 2023, 2022 and 2021, respectively. The Housekeeping services include managing customers’ housekeeping departments, which are principally responsible for the cleaning, disinfecting and sanitizing of resident rooms and common areas of the customers’ facilities, as well as the laundering and processing of the bed linens, uniforms, resident personal clothing and other assorted linen items utilized at the customers’ facilities. Upon beginning service with a customer facility, the Company will typically hire and train the employees previously employed by such facility and assign an on-site manager to supervise and train the front-line personnel and coordinate housekeeping services with other facility support functions in accordance with customer requests. Such management personnel also oversee the execution of various cost and quality control procedures including continuous training and employee evaluation. Dietary Dietary services accounted for $904.7 million, $894.5 million and $820.6 million of the Company’s consolidated revenues for the years ended December 31, 2023, 2022 and 2021, respectively. Dietary services consist of managing customers’ dietary departments which are principally responsible for food purchasing, meal preparation and professional dietitian services, which include the development of menus that meet the dietary needs of residents. On-site management is responsible for all daily dietary department activities, with regular support provided by a District Manager specializing in dietary services. The Company also offers clinical consulting services to facilities which if contracted is a service bundled within the monthly service provided to customers. Upon beginning service with a customer facility, the Company will typically hire and train the employees previously employed by such facility and assign an on-site manager to supervise and train the front-line personnel and coordinate dietitian services with other facility support functions in accordance with customer requests. Such management personnel also oversee the execution of various cost and quality control procedures including continuous training and employee evaluation. Revenue Recognition The Company’s revenues are derived from contracts with customers. The Company recognizes revenue to depict the transfer of promised goods and services to customers in amounts that reflect the consideration to which the Company is entitled in exchange for those goods and services. The Company’s costs of obtaining contracts are not material. The Company performs services and provides goods in accordance with its contracts with its customers. Such contracts typically provide for a renewable one year service term, cancellable by either party upon 30 to 90 days’ notice, after an initial period of 60 to 120 days. A performance obligation is the unit of account under Accounting Standards Codification (“ASC”) 606 and is defined as a promise in a contract to transfer a distinct good or service to the customer. The Company’s Housekeeping and Dietary contracts relate to the provision of bundles of goods, services or both, which represent a series of distinct goods and services that are substantially the same and that have the same pattern of transfer to the customer. The Company accounts for the series as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. Revenue is recognized using the output method, which is based upon the delivery of goods and services to the customers’ facilities. In limited cases, the Company provides goods, services or both before the execution of a written contract. In these cases, the Company defers the recognition of revenue until a contract is executed. The amount of such deferred revenue was less than $0.1 million and $0.3 million as of December 31, 2023 and 2022, respectively. Additionally, all such revenue amounts deferred as of December 31, 2022 were subsequently recognized as revenue during the year ended December 31, 2023. The transaction price is the amount of consideration to which the Company is entitled in exchange for transferring promised goods or services to its customers. The transaction price does not include taxes assessed or collected. The Company’s contracts detail the fees that the Company charges for the goods and services it provides. For certain contracts which contain a variable component to the transaction price, the Company is required to make estimates of the amount of consideration to which the Company will be entitled, based on variability in resident and patient populations serviced, product usage, quantities consumed or history of implicit price concessions. The Company recognizes revenue related to such estimates when the Company determines that it is probable there will not be a significant reversal in the amount of revenue recognized. In instances where variable consideration exists and management’s estimate of variable consideration changes in subsequent periods, resulting in a change in transaction price, the Company records an adjustment to revenue on a cumulative catch-up basis. The Company’s contracts generally do not contain significant financing components, as payment terms are less than one year. During the year ended December 31, 2023, the Company recorded an adjustment to revenues to reflect the Company’s change in estimate for price concessions based on new facts and circumstances related to a client’s out-of-court restructuring. Such adjustment reflects the Company’s current anticipated concession to be granted on certain amounts due as the Company’s current operating plans are to maintain providing services under this arrangement. For the year ended December 31, 2023, the adjustment was a $13.8 million reduction to revenue. During the year ended December 31, 2022, the Company recognized a reduction to revenues of $10.0 million related to the resolution of a previously offered variable consideration. The Company allocates the transaction price to each performance obligation, noting that the bundle of goods, services or goods and services provided under each Housekeeping and Dietary contract represents a single performance obligation that is satisfied over time. The Company recognizes the related revenue when it satisfies the performance obligation by transferring a bundle of promised goods, services or both to a customer. Such recognition is on a monthly or weekly basis, as goods are provided and services are performed. In some cases, the Company requires customers to pay in advance for goods and services to be provided. As of December 31, 2023 and 2022, the value of the contract liabilities associated with customer prepayments was $3.2 million and $3.1 million, respectively. The Company recognized $1.8 million of revenue during the year ended December 31, 2023 which was recorded as a contract liability on December 31, 2022. Transaction Price Allocated to Remaining Performance Obligations The Company recognizes revenue as it satisfies the performance obligations associated with contracts with customers, which due to the nature of the goods and services provided by the Company, are satisfied over time. Contracts may contain transaction prices that are fixed, variable or both. The Company’s contracts with customers typically provide for an initial term of one year, with renewable one year service terms, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days. At December 31, 2023, the Company had $13.7 million related to performance obligations that were unsatisfied or partially unsatisfied for which the Company expects to recognize revenue. The Company expects to recognize revenue on approximately 100.0% of the remaining performance obligations over the next 12 months. These amounts exclude variable consideration primarily related to performance obligations that consists of a series of distinct service periods with revenues based on future performance that cannot be estimated at contract inception. The Company also has elected to apply the practical expedient that permits exclusion of information about the remaining performance obligations with original expected durations of one year or less. |
Accounts and Notes Receivable
Accounts and Notes Receivable | 12 Months Ended |
Dec. 31, 2023 | |
Receivables [Abstract] | |
Accounts and Notes Receivable | Note 4 — Accounts and Notes Receivable The Company’s accounts and notes receivable balances consisted of the following as of December 31, 2023 and 2022: December 31, 2023 December 31, 2022 (in thousands) Short-term Accounts and notes receivable $ 470,759 $ 406,969 Allowance for doubtful accounts (87,250) (70,192) Total net short-term accounts and notes receivable $ 383,509 $ 336,777 Long-term Notes receivable $ 29,281 $ 35,882 Allowance for doubtful accounts (4,449) (3,273) Total net long-term notes receivable $ 24,832 $ 32,609 Total net accounts and notes receivable $ 408,341 $ 369,386 The Company makes credit decisions on a case-by-case basis after reviewing a number of qualitative and quantitative factors related to the specific customer as well as current industry variables that may impact that customer. There are a variety of factors that impact a customer’s ability to pay in accordance with the Company’s contracts. These factors include, but are not limited to, fluctuating census numbers, litigation costs and the customer’s participation in programs funded by federal and state governmental agencies. Deviations in the timing or amounts of reimbursements under those programs can impact the customer’s cash flows and its ability to make timely payments. However, the customer’s obligation to pay the Company in accordance with the contracts are not contingent upon the customer’s cash flow. Notwithstanding the Company’s efforts to minimize its credit risk exposure, the aforementioned factors, as well as other factors that impact customer cash flows or ability to make timely payments, could have an indirect, yet material adverse effect on the Company’s consolidated results of operations and financial condition. Fluctuations in net accounts and notes receivable are generally attributable to a variety of factors including, but not limited to, the timing of cash receipts from customers and the inception, transition, modification or termination of customer relationships. The Company deploys significant resources and has invested in tools and processes to optimize Management’s credit and collections efforts. When appropriate, the Company utilizes interest-bearing promissory notes to enhance the collectability of amounts due, by instituting definitive repayment plans and providing a means by which to further evidence the amounts owed. In addition, the Company may amend contracts from full service to management-only arrangements, or adjust contractual payment terms, to accommodate customers who have in good faith established clearly-defined plans for addressing cash flow issues. These efforts are intended to minimize the Company’s collections risk. |
Allowance for Doubtful Accounts
Allowance for Doubtful Accounts | 12 Months Ended |
Dec. 31, 2023 | |
Receivables [Abstract] | |
Allowance for Doubtful Accounts | Note 5 — Allowance for Doubtful Accounts In making the Company’s credit evaluations, management considers the general collection risk associated with trends in the long-term care industry. The Company establishes credit limits through payment terms with customers, performs ongoing credit evaluations and monitors accounts on an aging schedule basis to minimize the risk of loss. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future industry trends change in such a manner as to negatively impact their cash flows. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s customers experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s consolidated results of operations and financial condition. The Company evaluates its accounts and notes receivable for expected credit losses quarterly. Accounts receivable are evaluated based on internally developed credit quality indicators derived from the aging of receivables. Notes receivable are evaluated based on internally developed credit quality indicators derived from management’s assessment of collection risk. The Company manages the accounts and notes receivable portfolios using a two-tiered approach by disaggregating standard notes receivables, which are invoices or promissory notes in good standing, from those who have been identified by management as having an elevated credit risk profile due to a triggering event such as bankruptcy. At the end of each period, the Company sets a reserve for expected credit losses on standard accounts and notes receivable based on the Company’s historical loss rates. Accounts and notes receivable with an elevated risk profile, which are from customers who have filed bankruptcy, are subject to collections activity or are slow payers that are experiencing financial difficulties, are aggregated and evaluated to determine the total reserve for the class of receivable. ASC 326 permits entities to make an accounting policy election not to measure an estimate for credit losses on accrued interest if those entities write-off accrued interest deemed uncollectible in a timely manner. The Company follows an income recognition policy on all interest earned on notes receivable. Under such policy the Company accounts for all notes receivable on a non-accrual basis and defers the recognition of any interest income until receipt of cash payments. This policy was established based on the Company’s history of collections of interest on outstanding notes receivable, as we do not deem it probable that we will receive substantially all interest on outstanding notes receivable. For the years ended December 31, 2023, 2022 and 2021, the Company recognized $2.8 million, $1.1 million and $1.2 million in interest income from notes receivable, respectively. The following tables present the Company’s two tiers of notes receivable for the years ended December 31, 2023 and 2022, respectively, further disaggregated by year of origination, as well as write-off activity: Notes Receivable as of December 31, 2023 Amortized Cost Basis by Origination Year 2023 2022 2021 2020 2019 Prior Total (in thousands) Notes Receivable Standard notes receivable $ 18,175 $ 25,505 $ 855 $ 1,529 $ 3 $ 21,033 $ 67,100 Elevated risk notes receivable $ — $ — $ 7,259 $ — $ — $ — $ 7,259 Current-period gross write-offs $ — $ 189 $ — $ — $ 50 $ 2,253 $ 2,492 Current-period recoveries — — — — — — — Current-period net write-offs $ — $ 189 $ — $ — $ 50 $ 2,253 $ 2,492 Notes Receivable as of December 31, 2022 Amortized Cost Basis by Origination Year 2022 2021 2020 2019 2018 Prior Total (in thousands) Notes Receivable Standard notes receivable $ 31,406 $ 10,887 $ 1,683 $ 208 $ 13 $ 21,982 $ 66,179 Elevated risk notes receivable $ — $ — $ — $ — $ — $ 1,223 $ 1,223 Current-period gross write-offs $ 1 $ — $ 51 $ 54 $ — $ 491 $ 597 Current-period recoveries — — — — — — — Current-period net write-offs $ 1 $ — $ 51 $ 54 $ — $ 491 $ 597 The following tables provide information as to the status of payment on the Company’s gross notes receivable which were past due as of December 31, 2023 and 2022, respectively: Age Analysis of Past-Due Notes Receivable as of December 31, 2023 0-90 Days 91 - 180 Days Greater than 181 Days Total (in thousands) Notes Receivable Standard notes receivable $ 3,851 $ 4,852 $ 6,914 $ 15,617 Elevated risk notes receivable 569 569 949 2,087 $ 4,420 $ 5,421 $ 7,863 $ 17,704 Age Analysis of Past-Due Notes Receivable as of December 31, 2022 0-90 Days 91 - 180 Days Greater than 181 Days Total (in thousands) Notes Receivable Standard notes receivable $ 894 $ 263 $ 3,330 $ 4,487 Elevated risk notes receivable — — 1,223 1,223 $ 894 $ 263 $ 4,553 $ 5,710 The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the years ended December 31, 2023 and 2022, respectively: Allowance for doubtful accounts Portfolio Segment: December 31, Write-Offs 1 Bad Debt Expense December 31, (in thousands) Accounts receivable $ 66,601 $ (14,877) $ 29,095 $ 80,819 Notes receivable Standard notes receivable $ 6,052 $ (1,646) $ 1,719 $ 6,125 Elevated risk notes receivable 811 (846) 4,790 4,755 Total notes receivable $ 6,863 $ (2,492) $ 6,509 $ 10,880 Total accounts and notes receivable $ 73,464 $ (17,369) $ 35,604 $ 91,699 1. Write-offs are shown net of recoveries. During the year ended December 31, 2023, the Company collected $0.2 million of accounts receivables that were recovered subsequent to being written-off. Allowance for doubtful accounts Portfolio Segment: December 31, Write-Offs/Adjustments 1 Bad Debt Expense December 31, (in thousands) Accounts receivable $ 50,794 $ (16,825) $ 32,632 $ 66,601 Notes receivable Standard notes receivable $ 13,607 $ (6,783) $ (772) $ 6,052 Elevated risk notes receivable 1,183 (481) 109 811 Total notes receivable $ 14,790 $ (7,264) $ (663) $ 6,863 Total accounts and notes receivable $ 65,584 $ (24,089) $ 31,969 $ 73,464 1. |
Changes in Accumulated Other Co
Changes in Accumulated Other Comprehensive (Loss) Income by Component | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Changes in Accumulated Other Comprehensive (Loss) Income by Component | Note 6 — Changes in Accumulated Other Comprehensive (Loss) Income by Component For the years ended December 31, 2023, 2022 and 2021, the Company’s accumulated other comprehensive (loss) income consisted of unrealized gains and losses from the Company’s available-for-sale marketable securities. The following tables provide a summary of the changes in accumulated other comprehensive income, net of taxes: Unrealized Gains and (Losses) on Available-for-Sale Securities 1 Year Ended December 31, 2023 2022 2021 (in thousands) Accumulated other comprehensive (loss) income — beginning balance $ (3,477) $ 4,000 $ 5,563 Other comprehensive income (loss) before reclassifications 1,624 (7,505) (1,522) Losses (gains) reclassified from other comprehensive income 2 9 28 (41) Net current period other comprehensive income (loss) 3 1,633 (7,477) (1,563) Accumulated other comprehensive (loss) income — ending balance $ (1,844) $ (3,477) $ 4,000 1. All amounts are net of tax. 2. Realized gains and losses were recorded pre-tax under “Investment and other income (loss), net” in the Consolidated Statements of Comprehensive Income. For the years ended December 31, 2023 and 2022, the Company recorded less than $0.1 million of realized losses from the sale of available-for-sale securities. For the year ended December 31, 2021, the Company recorded $0.1 million of realized gains from the sale of available-for-sale securities. Refer to Note 10 — Fair Value Measurements herein for further information. 3. For the year ended December 31, 2023, the change in other comprehensive (loss) income was net of a tax expense of $0.4 million. For the years ended December 31, 2022 and 2021, the changes in other comprehensive (loss) income were net of a tax benefit of $2.0 million and benefit of $0.4 million, respectively. Amounts Reclassified from Accumulated Other Comprehensive (Loss) Income 2023 2022 2021 (in thousands) Year Ended December 31, (Losses) gains from the sale of available-for-sale securities $ (12) $ (37) $ 55 Tax benefit (expense) 3 9 (14) Net (loss) gain reclassified from accumulated other comprehensive income $ (9) $ (28) $ 41 |
Property and Equipment
Property and Equipment | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment, Net | Note 7 — Property and Equipment Property and equipment are recorded at cost. Depreciation is recorded over the estimated useful life of each class of depreciable asset and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred. The following table sets forth the amounts of property and equipment by each class of depreciable asset as of December 31, 2023 and December 31, 2022: December 31, 2023 December 31, 2022 (in thousands) Housekeeping and Dietary equipment $ 15,764 $ 13,585 Computer hardware and software 6,870 6,086 Operating lease — right-of-use assets 27,099 34,445 Other 1 1,070 1,055 Total property and equipment, at cost 50,803 55,171 Less accumulated depreciation 2 22,029 32,196 Total property and equipment, net $ 28,774 $ 22,975 1. Includes furniture and fixtures, leasehold improvements and autos and trucks. 2. Includes $9.4 million and $22.1 million related to accumulated depreciation on Operating lease – right-of-use assets as of December 31, 2023 and 2022, respectively. Depreciation expense for the years ended December 31, 2023, 2022 and 2021 was $10.5 million, $10.5 million, and $10.3 million, respectively. Of the depreciation expense recorded for the years ended December 31, 2023, 2022 and 2021 $6.4 million, $6.1 million and $6.4 million related to the depreciation of the Company’s operating lease - right-of-use assets (“ROU Assets”), respectively. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Leases | Note 8 — Leases The Company recognizes ROU assets and lease liabilities for automobiles, office buildings, IT equipment and small storage units for the temporary storage of operational equipment. The Company’s leases have remaining lease terms ranging from less than 1 year to 5 years, and have extension options ranging from 1 year to 5 years. Most leases include the option to terminate the lease within 1 year. The Company uses practical expedients offered under the ASC 842 guidance to combine lease and non-lease components within leasing arrangements and to recognize the payments associated with short-term leases in earnings on a straight-line basis over the lease term, with the cost associated with variable lease payments recognized when incurred. These accounting policy elections impact the value of the Company’s ROU assets and lease liabilities. The value of the Company’s ROU assets is determined as the carrying value of its leasing arrangements and is recorded in Property and equipment, net on the Company’s Consolidated Balance Sheets. The value of the Company’s lease liabilities is the present value of fixed lease payments not yet paid, which is discounted using either the rate implicit in the lease contract if that rate can be determined or the Company’s incremental borrowing rate ( “ IBR”) and is recorded in Other accrued expenses and current liabilities and Lease liability — long-term on the Company’s Consolidated Balance Sheets. The Company’s IBR is determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. Any future lease payments that are not fixed based on the terms of the lease contract, or fluctuate based on a factor other than an index or rate, are considered variable lease payments and are not included in the value of the Company’s ROU assets or lease liabilities. The Company’s IBR is determined as the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. As of December 31, 2023 and 2022, the Company’s short-term portion of lease obligations were $7.4 million and $5.3 million, respectively, and are recorded in Other accrued expenses and current liabilities Components of lease expense are presented below for the years ended December 31, 2023, 2022 and 2021. Year Ended December 31, 2023 2022 2021 (in thousands) Lease cost Operating lease cost $ 6,400 $ 5,673 $ 6,210 Short-term lease cost 1,037 1,265 747 Variable lease cost 1,952 857 973 Total lease cost $ 9,389 $ 7,795 $ 7,930 Supplemental information is presented below for the years ended December 31, 2023, 2022 and 2021. Year Ended December 31, 2023 2022 2021 (dollar amounts in thousands) Other information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 6,808 $ 6,385 $ 6,609 ROU Assets obtained in exchange for lease obligations $ 6,064 1,650 7,143 Weighted-average remaining lease term — operating leases 3.3 years 4.2 years 4.5 years Weighted-average discount rate — operating leases 6.6 % 4.4 % 4.2 % During the years ended December 31, 2023 and 2022, the Company’s ROU assets and lease liabilities were reduced by $2.7 million and $1.7 million, respectively due to lease cancellations. The following is a schedule by calendar year of future minimum lease payments under operating leases that have remaining terms as of December 31, 2023: Period/Year Operating Leases (in thousands) 2024 $ 7,365 2025 6,617 2026 3,768 2027 1,365 2028 1,389 Thereafter 116 Total minimum lease payments $ 20,620 Less: imputed lease payments 1,999 Present value of lease liabilities $ 18,621 |
Goodwill and Other Intangible A
Goodwill and Other Intangible Assets | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Other Intangible Assets | Note 9 — Goodwill and Other Intangible Assets Goodwill Goodwill represents the excess of the purchase price over the fair value of net assets of acquired businesses. Goodwill is not amortized but is evaluated for impairment on an annual basis or more frequently if impairment indicators arise. To date, the Company has not recognized an impairment of its goodwill. The following table sets forth the amounts of goodwill by reportable segment as of December 31, 2023 and 2022: December 31, 2023 December 31, 2022 (in thousands) Housekeeping $ 42,377 $ 42,377 Dietary 33,152 33,152 Total Goodwill $ 75,529 $ 75,529 Intangible Assets The Company’s other intangible assets consist of customer relationships, trade names, patents and non-compete agreements which were obtained through acquisitions and are recorded at their fair values at the date of acquisition. The following table sets forth the amounts of other intangible assets as of December 31, 2023 and 2022: December 31, 2023 December 31, 2022 Gross Amount Accumulated Amortization Net Amount Gross Amount Accumulated Amortization Net Amount (in thousands) Customer relationships $ 45,634 $ 35,718 $ 9,916 $ 45,634 $ 32,211 $ 13,423 Trade names 1,731 329 1,402 1,731 191 1,540 Patents 1,086 369 717 1,086 232 854 Non-compete agreements 233 141 92 233 104 129 Total other intangible assets $ 48,684 $ 36,557 $ 12,127 $ 48,684 $ 32,738 $ 15,946 No acquisitions occurred during the year ended December 31, 2023. Intangible assets with determinable useful lives are amortized on a straight-line basis over their estimated useful lives. The weighted-average amortization period of customer relationships, trade names, patents, and non-compete agreements are approximately 10 years, 13 years, 8 years and 4 years, respectively. The following table sets forth the estimated amortization expense for intangibles subject to amortization for 2024, the following four fiscal years and thereafter: Period/Year Total Amortization Expense (in thousands) 2024 $ 2,685 2025 $ 2,685 2026 $ 2,666 2027 $ 1,196 2028 $ 613 Thereafter $ 2,282 Total $ 12,127 Amortization expense for the years ended December 31, 2023, 2022 and 2021 was $3.8 million, $4.9 million and $4.4 million, respectively. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Note 10 — Fair Value Measurements The Company’s current assets and current liabilities are financial instruments and most of these items (other than marketable securities, inventories and the short-term portion of deferred compensation funding) are recorded at cost in the Consolidated Balance Sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature. The carrying value of the Company’s line of credit represents the outstanding amount of the borrowings, which approximates fair value. The Company’s financial assets that are measured at fair value on a recurring basis are its marketable securities and deferred compensation funding. The recorded values of all of the financial instruments approximate their current fair values because of their nature, stated interest rates and respective maturity dates or durations. The Company’s marketable securities are held by the Company’s captive insurance company to satisfy capital requirements of the state regulator related to captive insurance companies. Such securities primarily consist of tax-exempt municipal bonds, which are classified as available-for-sale and are reported at fair value. Unrealized gains and losses associated with these investments are included in Unrealized gain (loss) on available-for-sale marketable securities, net of taxes within the Consolidated Statements of Comprehensive Income. The fair value of these marketable securities is classified within Level 2 of the fair value hierarchy, as these securities are measured using quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable. Such valuations are determined by a third-party pricing service. For the year ended December 31, 2023, the Company recorded unrealized gains, net of taxes of $1.6 million on marketable securities. For the years ended December 31, 2022 and 2021, the Company recorded unrealized losses, net of taxes of $7.5 million and $1.6 million on marketable securities, respectively. For the years ended December 31, 2023, 2022 and 2021, the Company received total proceeds, less the amount of interest received, of $2.0 million, $10.4 million and $26.7 million, respectively, from sales of available-for-sale municipal bonds. For both years ended December 31, 2023 and 2022, these sales each resulted in realized losses of less than $0.1 million, and realized gains of less than $0.1 million for the year ended December 31, 2021. Such gains and losses were recorded in Investment and other income (loss), net in the Consolidated Statements of Comprehensive Income. The basis for the sale of these securities was the specific identification of each bond sold during the period. As part of a 2021 acquisition of a prepackaged meal manufacturer, the Company agreed to pay royalties to the seller on all future product sales. The Company recorded a liability for the expected future payments within Other long-term liabilities on the Consolidated Balance Sheets. The fair value of this liability is measured using forecasted sales models (Level 3). For the years ended December 31, 2023, 2022 and 2021, the Company recorded realized gains of $1.1 million, $2.4 million and $0.1 million, respectively, within Costs of services provided in the Consolidated Statements of Comprehensive Income related to the subsequent measurement of the liability at each balance sheet date. The investments under the funded deferred compensation plan are accounted for as trading securities and unrealized gains or losses are recorded within other income (expense), net in the Consolidated Statements of Comprehensive Income. The fair value of these investments, excluding amounts held in money market accounts, is determined based on quoted market prices (Level 1). The fair value of money market accounts is measured using quoted prices for identical or similar instruments in markets that are not active (Level 2). For the years ended December 31, 2023, 2022 and 2021, the Company recorded unrealized gains of $6.6 million, losses of $9.3 million and gains of $6.5 million, respectively, related to equity securities still held at the respective reporting dates. The following tables provide fair value measurement information for the Company’s marketable securities and deferred compensation fund investments as of December 31, 2023 and December 31, 2022: As of December 31, 2023 Fair Value Measurement Using: Carrying Amount Total Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in thousands) Financial Assets: Marketable securities Municipal bonds — available-for-sale $ 93,131 $ 93,131 $ — $ 93,131 $ — Deferred compensation fund Money Market 1 $ 2,007 $ 2,007 $ — $ 2,007 $ — Commodities 298 298 298 — — Fixed Income 4,254 4,254 4,254 — — International 4,621 4,621 4,621 — — Large Cap Blend 5,053 5,053 5,053 — — Large Cap Growth 13,886 13,886 13,886 — — Large Cap Value 5,964 5,964 5,964 — — Mid Cap Blend 3,192 3,192 3,192 — — Real Estate 374 374 374 — — Small Cap Blend 2,664 2,664 2,664 — — Deferred compensation fund 2 $ 42,313 $ 42,313 $ 40,306 $ 2,007 $ — As of December 31, 2022 Fair Value Measurement Using: Carrying Total Fair Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in thousands) Financial Assets: Marketable securities Municipal bonds — available-for-sale $ 95,200 $ 95,200 $ — $ 95,200 $ — Deferred compensation fund Money Market 1 $ 2,420 $ 2,420 $ — $ 2,420 $ — Commodities 170 170 170 — — Fixed Income 3,571 3,571 3,571 — — International 4,093 4,093 4,093 — — Large Cap Blend 1,210 1,210 1,210 — — Large Cap Growth 11,064 11,064 11,064 — — Large Cap Value 6,133 6,133 6,133 — — Mid Cap Blend 2,667 2,667 2,667 — — Real Estate 359 359 359 — — Small Cap Blend 3,424 3,424 3,424 — — Deferred compensation fund 2 $ 35,111 $ 35,111 $ 32,691 $ 2,420 $ — 1. The fair value of the money market fund is based on the net asset value (“NAV”) of the shares held by the fund at the end of the period. The money market fund includes short-term United States dollar denominated money market instruments and the NAV is determined by the custodian of the fund. The money market fund can be redeemed at its NAV at the measurement date as there are no significant restrictions on the ability to sell this investment. 2. The deferred compensation fund carrying amounts and total fair value amounts as of December 31, 2023 and 2022 are inclusive of $1.5 million and $1.6 million of holdings expected to be paid to former employees within the next twelve months and were recorded under Prepaid expenses and other assets in the Company’s Consolidated Balance Sheets. Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Impairments (in thousands) December 31, 2023 Type of security: Municipal bonds — available-for-sale $ 95,466 $ 387 $ (2,722) $ 93,131 $ — Total debt securities $ 95,466 $ 387 $ (2,722) $ 93,131 $ — December 31, 2022 Type of security: Municipal bonds — available-for-sale $ 99,601 $ 229 $ (4,630) $ 95,200 $ — Total debt securities $ 99,601 $ 229 $ (4,630) $ 95,200 $ — The following table summarizes the contractual maturities of debt securities held at December 31, 2023 and December 31, 2022, which are classified as marketable securities in the Company’s Consolidated Balance Sheets: Municipal Bonds — Available-for-Sale Contractual maturity: December 31, 2023 December 31, 2022 (in thousands) Maturing in one year or less $ 6,324 $ 2,798 Maturing in second year through fifth year 34,939 35,068 Maturing in sixth year through tenth year 39,309 38,575 Maturing after ten years 12,559 18,759 Total debt securities $ 93,131 $ 95,200 |
Share-Based Compensation
Share-Based Compensation | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Share-Based Compensation | Note 11 — Share-Based Compensation The components of the Company’s share-based compensation expense for the years ended December 31, 2023, 2022 and 2021 are as follows: Year Ended December 31, 2023 2022 2021 (in thousands) Stock options $ 969 $ 1,253 $ 1,832 Restricted stock, restricted stock units and deferred stock units 6,657 6,972 6,367 Performance stock units 1,210 819 401 Employee Stock Purchase Plan 149 170 227 Total pre-tax share-based compensation expense charged against income $ 8,985 $ 9,214 $ 8,827 Total recognized tax deficiency related to share-based compensation $ (773) $ (783) $ (217) The following table summarizes the components of share-based compensation expense included within the Consolidated Statements of Comprehensive Income for the years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 (in thousands) Selling, general & administrative expense $ 8,942 $ 9,160 $ 8,767 Costs of services provided 43 54 60 Total $ 8,985 $ 9,214 $ 8,827 At December 31, 2023 and 2022, the unrecognized compensation cost related to unvested stock options and awards was $16.5 million and $15.8 million, respectively. The weighted average period over which these awards will vest was approximately 2.8 years as of both December 31, 2023 and December 31, 2022. Amended 2020 Omnibus Incentive Plan On May 26, 2020, the Company adopted the 2020 Omnibus Incentive Plan (the “2020 Plan”) after approval by the Company’s shareholders. On May 30, 2023, the Company increased the authorized shares under the 2020 Omnibus Incentive Plan (as amended, the “Amended 2020 Plan”) by 2,500,000 shares after approval by the Company’s shareholders at the 2023 Annual Meeting of Shareholders. The Amended 2020 Plan provides that current or prospective officers, employees, non-employee directors and advisors can receive share-based awards such as stock options, performance stock units, restricted stock units and other stock awards. The Amended 2020 Plan seeks to encourage profitability and growth of the Company through short-term and long-term incentives that are consistent with the Company’s operating objectives. As of December 31, 2023, there were 7.0 million shares of common stock reserved for issuance under the Amended 2020 Plan, of which 3.2 million are available for future grant. The amount of shares available for issuance under the Amended 2020 Plan will increase when outstanding awards under the Company’s Second Amended and Restated 2012 Equity Incentive Plan (the “2012 Plan”) are subsequently forfeited, terminated, lapsed or satisfied thereunder in cash or property other than shares. No stock award will have a term in excess of 10 years. The Nominating, Compensation and Stock Option Committee (the “NCSO”) of the Board of Directors is responsible for determining the terms of the grants in accordance with the Amended 2020 Plan. Stock Options A summary of stock options outstanding under the Amended 2020 Plan and the 2012 Plan as of December 31, 2023, December 31, 2022 and changes during the year ended December 31, 2023 are as follows: Stock Options Outstanding Number of Shares Weighted Average Exercise Price (in thousands) December 31, 2022 2,375 $ 31.56 Granted 207 $ 13.72 Exercised — $ — Forfeited — $ — Expired (144) $ 24.99 December 31, 2023 2,438 $ 30.43 The weighted average grant-date fair value of stock options granted during the years ended December 31, 2023, 2022 and 2021 was $6.53, $4.06 and $7.01 per common share, respectively. No stock options were exercised during the year ended December 31, 2023. The total intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was $0.1 million and $0.7 million, respectively. The total fair value of stock options vested during the years ended December 31, 2023, 2022 and 2021 were $1.3 million, $1.8 million and $2.1 million, respectively. For the year ended December 31, 2023 there was no tax deficiency realized from stock options exercised. For the years ended December 31, 2022 and 2021 the tax deficiency realized from stock options exercised was immaterial. The fair value of stock option awards granted in 2023, 2022 and 2021 were estimated on the dates of grant using the Black-Scholes option valuation model with the following assumptions: Year Ended December 31, 2023 2022 2021 Risk-free interest rate 4.0 % 1.5 % 0.6 % Weighted average expected life 6.9 years 6.7 years 6.6 years Expected volatility 39.5 % 36.6 % 34.7 % Dividend yield — % 4.6 % 2.9 % The following table summarizes other information about the stock options at December 31, 2023: December 31, 2023 (amounts in thousands, except per share data) Outstanding: Aggregate intrinsic value $ — Weighted average remaining contractual life 4.5 years Exercisable: Number of options 1,702 Weighted average exercise price $ 34.72 Aggregate intrinsic value $ — Weighted average remaining contractual life 2.6 years Restricted Stock Units The fair value of outstanding restricted stock units was determined based on the market price of the shares on the date of grant. During the years ended December 31, 2023, 2022 and 2021, the Company granted 0.5 million, 0.4 million and 0.3 million restricted stock units with weighted average grant date fair values of $13.72, $18.06 and $28.53 per unit, respectively. A summary of the outstanding restricted stock units as of December 31, 2023, December 31, 2022 and changes during the year ended December 31, 2023 is as follows: Restricted Stock Units Number Weighted Average Grant Date Fair Value (in thousands) December 31, 2022 825 $ 24.37 Granted 536 $ 13.72 Vested (237) $ 27.82 Forfeited (22) $ 18.76 December 31, 2023 1,102 $ 18.57 The weighted average remaining vesting period for the unvested restricted stock units is 3.1 years. The weighted average grant-date fair values and total fair values of restricted stock units vested during 2023, 2022 and 2021 were as follows: Year Ended December 31, 2023 2022 2021 (in thousands, except per share data) Weighted average grant-date fair value of restricted stock units granted $ 13.72 $ 18.06 $ 28.53 Total fair value of restricted stock units and restricted shares vested $ 2,991 $ 3,307 $ 4,185 Performance Stock Units On February 24, 2023, the NCSO granted 80,000 Performance Stock Units (“PSUs”) to the Company’s executive officers. Such PSUs are contingent upon the achievement of certain total shareholder return (“TSR”) targets as compared to the TSR of the S&P 400 MidCap Index and the participant’s continued employment with the Company for the three year period ending December 31, 2025, the date at which such awards vest. The unrecognized share-based compensation cost of the TSR-based PSU awards at December 31, 2023 is $1.3 million and is expected to be recognized over a weighted-average period of 1.4 years. A summary of the outstanding PSUs as of December 31, 2023, December 31, 2022 and changes during the year ended December 31, 2023 is as follows: Performance Stock Units Number Weighted Average Grant Date Fair Value (in thousands) December 31, 2022 95 $ 26.01 Granted 80 $ 16.20 Vested — $ — Forfeited — $ — December 31, 2023 175 $ 21.52 Deferred Stock Units The Company grants Deferred Stock Units (“DSUs”) to the Company’s non-employee directors. Once vested, the recipient shall be entitled to receive a lump sum payment of a number of shares equal to the total number of DSUs issued to such recipient upon the first to occur of (i) the five year anniversary of the date of grant, (ii) the recipient’s death, disability or separation of service from the Board, or (iii) a change of control (as defined by the Amended 2020 Plan). Non-employee directors can also elect to receive their Board of Directors retainer in the form of DSUs in lieu of cash. DSUs issued in lieu of cash for retainers vest immediately. The number of DSUs granted to these directors is determined based on the stock price on the award date and approximates the cash value the directors would otherwise receive for their retainer. Two non-employee directors made an election in 2022 to receive DSUs in lieu of cash for their 2023 Board of Directors retainer. On May 30, 2023, the NCSO granted an aggregate of 23,000 DSUs to the Company’s non-employee directors. Each DSU award granted vests in one year. The unrecognized share-based compensation cost of DSU awards at December 31, 2023 is $0.1 million and is expected to be recognized over a weighted-average period of 0.4 years. Employee Stock Purchase Plan The Company’s Employee Stock Purchase Plan (“ESPP”) is currently available through 2026 to all eligible employees. All full-time and part-time employees who work an average of 20 hours per week and have completed two years of continuous service with the Company are eligible to participate. Annual offerings commence and terminate on the respective year’s first and last calendar day. Under the ESPP, the Company is authorized to issue up to 4.1 million shares of its common stock to its employees. Pursuant to such authorization, there are 1.8 million shares available for future grant at December 31, 2023. Under the terms of the ESPP, participants may contribute through payroll deductions up to $21,250 (85% of IRS limitation) of their compensation toward the purchase of the Company’s common stock. No employee may purchase common stock which exceeds $25,000 in fair market value (determined on the option date) for each calendar year. The per option price is equal to the lower of 85% of the fair market price on the first day of the offering period, or 85% of the fair market price on the last day of the offering period. The following table summarizes information about the Company’s ESPP annual offerings for the years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 (in thousands, except per share data) Common shares purchased 95 95 85 Per common share purchase price $ 8.81 $ 10.20 $ 15.12 The expense associated with the options granted under the ESPP during the year ended December 31, 2023 and 2022 was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions: Year Ended December 31, 2023 2022 Risk-free interest rate 4.8% 0.4% Weighted average expected life (years) 1.0 1.0 Expected volatility 42.9% 36.9% Dividend yield 7.1% 4.7% Deferred Compensation Plan The Company offers a Supplemental Executive Retirement Plan (“SERP”) for executives and certain key employees. The SERP is not qualified under Section 401 of the Internal Revenue Code. The SERP allows participants to defer up to 25% of their earned income on a pre-tax basis and as of the last day of each plan year, each participant will be credited with a 25% match of up to 15% of their earnings deferred in the form of the Company’s common stock based on the then-current market value. SERP participants fully vest in the Company’s matching contribution three years from the first day of the initial year of participation. The income deferred and the matching contributions are unsecured and subject to the claims of the Company’s general creditors. Under the SERP, the Company is authorized to issue 1.0 million shares of its common stock to its employees. Pursuant to such authorization, the Company has 0.2 million shares available for future grant at December 31, 2023. At the time of issuance, such shares are accounted for at cost as treasury stock. At December 31, 2023, approximately 0.3 million of shares granted under the SERP are vested and remain in the respective active participants’ accounts with the trustee. The following table summarizes information about the SERP during the plan years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 (in thousands) SERP expense 1 $ 533 $ 486 $ 531 Treasury shares issued to fund SERP expense 2 50 40 30 Year end SERP trust account balance 3 $ 42,313 $ 35,111 $ 59,086 Unrealized gain (loss) recorded in SERP liability account $ 6,684 $ (9,178) $ 6,676 1. Both the SERP match and the deferrals are included in the selling, general and administrative caption in the Consolidated Statements of Comprehensive Income. 2. Shares related to the SERP match for each year are funded at the beginning of the subsequent year. 3. SERP trust account investments are recorded at their fair value which is based on quoted market prices. Differences between such amounts in the table above and the deferred compensation funding asset reported on the Company’s Consolidated Balance Sheets represent the value of Company common stock held in the Plan participants’ trust accounts and reported by the Company as treasury stock in the Company’s Consolidated Balance Sheets. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 12 — Income Taxes The following table summarizes the provision for income taxes: Year Ended December 31, 2023 2022 2021 (amounts in thousands) Current: Federal $ 13,728 $ 3,022 $ 9,120 State 5,762 2,381 3,766 $ 19,490 $ 5,403 $ 12,886 Deferred: Federal $ (4,183) $ 4,163 $ 3,127 State (637) 744 956 $ (4,820) $ 4,907 $ 4,083 Tax provision $ 14,670 $ 10,310 $ 16,969 Deferred income taxes are recorded using the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and income tax basis of assets and liabilities. Significant components of the Company’s federal and state deferred tax asset and liability balances were as follows: Year Ended December 31, 2023 2022 (in thousands) Deferred tax assets: Allowance for doubtful accounts $ 22,788 $ 18,139 Deferred compensation 9,048 8,686 Accrued insurance claims 5,580 5,609 Non-deductible reserves 169 256 Lease liabilities 4,765 5,709 Share based compensation 2,988 2,142 Other 2,418 2,848 $ 47,756 $ 43,389 Deferred tax liabilities: Expensing of housekeeping supplies $ (2,351) $ (2,510) Amortization of goodwill and intangibles (3,000) (2,389) Depreciation of property and equipment (1,688) (1,769) Lease right-of-use assets (4,571) (5,482) Other (920) (399) $ (12,530) $ (12,549) Net deferred tax assets $ 35,226 $ 30,840 Realization of the Company’s deferred tax assets is dependent upon future earnings in specific tax jurisdictions, the timing and amount of which are uncertain. Management assesses the Company’s income tax positions and records tax benefits for all years subject to examination based upon an evaluation of the facts, circumstances and information available at the reporting dates, which include historical operating results and expectations of future earnings. As such, management believes it is more likely than not that the deferred tax assets recorded will be realized to reduce future income taxes and therefore no valuation allowances are necessary. The table below provides a reconciliation between the tax expense computed by applying the statutory federal income tax rate to income before income taxes and the provision for income taxes: Year Ended December 31, 2023 2022 2021 (in thousands) Income tax expense computed at statutory rate $ 11,182 $ 9,356 $ 13,758 Increases (decreases) resulting from: State income taxes, net of federal tax benefit 4,153 2,594 4,165 Federal jobs credits (2,014) (2,571) (3,177) Tax exempt interest (348) (308) (324) Share-based compensation 1,610 1,250 1,072 Fines and penalties 55 4 1,294 Other, net 32 (15) 181 Income tax expense $ 14,670 $ 10,310 $ 16,969 The Company performs an evaluation each period of its tax positions taken and expected to be taken in tax returns. The evaluation is performed on positions relating to tax years that remain subject to examination by major tax jurisdictions, the earliest of which is the tax year ended December 31, 2018. Based on the evaluation, the Company concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. Therefore, the table reporting on the change in the liability for unrecognized tax benefits during the years ended December 31, 2023 and 2022 is omitted as there is no activity to report in such account for the years ended December 31, 2023 or 2022. |
Segment Information
Segment Information | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | Note 13 — Segment Information The Company manages and evaluates its operations in two reportable segments: Housekeeping (housekeeping, laundry, linen and other services) and Dietary (dietary department services). Although both segments serve a similar customer base and share many operational similarities, they are managed separately due to distinct differences in the type of services provided, as well as the specialized expertise required of the professional management personnel responsible for delivering each segment’s services. Such services are rendered pursuant to discrete contracts, specific to each reportable segment. The Company’s accounting policies for the segments are generally the same as described in the Company’s significant accounting policies. Differences between the reportable segments’ operating results and other disclosed data and the information in the Consolidated Financial Statements relate primarily to corporate level transactions and recording of transactions at the reportable segment level using other than generally accepted accounting principles. There are certain inventories and supplies that are primarily expensed when incurred within the operating segments, while they are capitalized in the consolidated financial statements. In addition, most corporate expenses such as corporate salary and benefit costs, certain legal costs, bad debt expense, information technology costs, depreciation, amortization of finite-lived intangible assets, share based compensation costs and other corporate-specific costs, are not fully allocated to the operating segments. There are also allocations for workers’ compensation and general liability expense within the operating segments that differ from the actual expense recorded by the Company under U.S. GAAP. Segment amounts disclosed are prior to elimination entries made in consolidation. All revenues and net income are earned in the United States. Year Ended December 31, 2023 2022 2021 (in thousands) Revenues 1 Housekeeping $ 766,651 $ 795,687 $ 821,329 Dietary 904,738 894,489 820,630 Total $ 1,671,389 $ 1,690,176 $ 1,641,959 Income before income taxes Housekeeping $ 61,311 $ 73,096 $ 79,380 Dietary 43,547 29,065 45,758 Corporate 2 (51,802) (57,608) (59,626) Total $ 53,056 $ 44,553 $ 65,512 Depreciation and amortization Housekeeping $ 4,380 $ 5,491 $ 5,399 Dietary 3,001 3,075 2,611 Corporate 6,963 6,750 6,657 Consolidated $ 14,344 $ 15,316 $ 14,667 Total assets Housekeeping $ 253,729 $ 250,444 $ 225,531 Dietary 291,550 263,126 221,911 Corporate 3 245,373 207,266 332,447 Consolidated $ 790,652 $ 720,836 $ 779,889 Capital expenditures Housekeeping $ 4,684 $ 4,412 $ 5,005 Dietary 494 499 451 Corporate 228 299 231 Consolidated $ 5,406 $ 5,210 $ 5,687 1. For the years ended December 31, 2023 and 2022, both the Housekeeping and Dietary segments earned revenue from several significant customers, although Genesis was the only customer to contribute more than 10% of consolidated revenue. For the years ended December 31, 2023, 2022 and 2021, Genesis accounted for $181.4 million or 10.9%, $169.1 million or 10.0% and $177.1 million or 10.8% of the Company’s consolidated revenues, respectively. 2. Primarily represents corporate office costs and related overhead, recording of certain inventories and supplies and workers compensation costs at the reportable segment level which use accounting methods that differ from those used at the corporate level, as well as consolidated subsidiaries’ operating expenses that are not allocated to the reportable segments, net of investment and other income and interest expense. 3. Primarily consists of cash and cash equivalents, marketable securities, deferred income taxes and other current and noncurrent assets. |
Earnings Per Common Share
Earnings Per Common Share | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Earnings Per Common Share | Note 14 — Earnings Per Common Share Basic and diluted earnings per common share are computed by dividing net income by the weighted-average number of basic and diluted common shares outstanding, respectively. The weighted-average number of diluted common shares includes the impact of dilutive securities, including outstanding stock options and unvested restricted stock and restricted stock units. The table below reconciles the weighted-average basic and diluted common shares outstanding for 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 Numerator for basic and diluted earnings per share: Net income $ 38,386 $ 34,243 $ 48,543 Denominator: Weighted average number of common shares outstanding - basic 74,288 74,336 74,816 Effect of dilutive securities 1 52 15 146 Weighted average number of common shares outstanding - diluted 74,340 74,351 74,962 Basic earnings per share: $ 0.52 $ 0.46 $ 0.65 Diluted earnings per share: $ 0.52 $ 0.46 $ 0.65 1. Certain outstanding equity awards are anti-dilutive and therefore were excluded from the calculation of the weighted-average number of diluted common shares outstanding. Anti-dilutive outstanding equity awards under share-based compensation plans were as follows: Year Ended December 31, 2023 2022 2021 (in thousands) Anti-dilutive equity awards 3,228 3,203 1,980 |
Other Contingencies
Other Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Other Contingencies | Note 15 — Other Contingencies Line of Credit At December 31, 2023, the Company had a $300 million bank line of credit on which to draw for general corporate purposes. Amounts drawn under the line of credit are payable upon demand and generally bear interest at a floating rate, based on the Company’s leverage ratio, and starting at Term Secured Overnight Financing Rate (“SOFR”) plus 165 basis points. As of December 31, 2023 and 2022 , there were $25.0 million of borrowings under the line of credit. The line of credit requires the Company to satisfy two financial covenants, with which the Company is in compliance as of December 31, 2023. The line of credit expires on November 22, 2027. The Company’s line of credit was amended on November 22, 2022 to, among other things, provide for a five-year unsecured revolving loan facility in the aggregate amount of $300 million with, at the Company’s option, the ability to increase the revolving loan commitments to an aggregate amount not to exceed $500 million and to change the benchmark rate from the London Interbank Offered Rate to SOFR. At December 31, 2023, the Company also had outstanding $85.9 million in irrevocable standby letters of credit, which relate to payment obligations under the Company’s insurance programs. In connection with the issuance of the letters of credit, the amount available under the line of credit was reduced by $85.9 million to $189.1 million at December 31, 2023. On December 29, 2023, January 2, 2024 and January 3, 2024, the letters of credit were renewed, and they all expire in the first quarter of 2025. Tax Jurisdictions and Matters The Company provides services throughout the continental United States and is subject to numerous state and local taxing jurisdictions. In the ordinary course of business, a jurisdiction may contest the Company’s reporting positions with respect to the application of its tax code to the Company’s services, which could result in additional tax liabilities. The Company has tax matters with various taxing authorities. Because of the uncertainties related to both the probable outcomes and amount of probable assessments due, the Company is unable to make a reasonable estimate of a liability. The Company does not expect the resolution of any of these matters, taken individually or in the aggregate, to have a material adverse effect on the consolidated financial position or results of operations based on the Company’s best estimate of the outcomes of such matters. Legal and Other Contingencies The Company is involved in litigation and other matters incidental to the conduct of its business, the results of which, in the opinion of management, are not likely to be material to the Company's financial condition, results of operations or cash flows. Government Regulations The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or additional changes in existing regulations could directly impact the governmental reimbursement programs in which the customers participate. |
Other Employee Benefit Plans
Other Employee Benefit Plans | 12 Months Ended |
Dec. 31, 2023 | |
Retirement Benefits [Abstract] | |
Other Employee Benefit Plans | Note 16 — Other Employee Benefit Plans Retirement Savings Plan Since October 1, 1999, the Company has had a retirement savings plan for eligible employees (the “RSP”) under Section 401(k) of the Internal Revenue Code. The RSP allows eligible employees to contribute up to 15% of their eligible compensation on a pre-tax basis. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 17 — Related Party Transactions For the years ended December 31, 2023, 2022 and 2021, the Company did not have any material related party transactions. |
Accrued Insurance Claims
Accrued Insurance Claims | 12 Months Ended |
Dec. 31, 2023 | |
Payables and Accruals [Abstract] | |
Accrued Insurance Claims | Note 18 — Accrued Insurance Claims The Company currently has a Paid Loss Retrospective Insurance Plan for general liability, workers’ compensation insurance and other self-insurance programs, which comprised approximately 25.3% and 29.3% of the Company’s liabilities at December 31, 2023 and 2022, respectively. Under the Company’s insurance plans, predetermined loss limits are arranged with the Company’s insurance company to limit both per occurrence cash outlay and annual insurance plan cost. The Company’s accounting for this plan utilizes current valuations from a third-party actuary, which include assumptions based on data such as historical claims, pay-out experience, demographic factors, industry trends, severity factors and other actuarial calculations. In the event that the Company’s claims experience and/or industry trends result in an unfavorable change in the assumptions or outcomes, it would have an adverse effect on the Company’s results of operations and financial condition. For general liability, workers’ compensation and other self-insurance programs, the Company records both a reserve for the estimated future cost of claims and related expenses that have been reported but not settled, as well as an estimate of claims incurred but not reported. General liability and workers’ compensation reserves for claims incurred but not reported are developed by a third party actuary through review of the Company’s historical data and open claims. In 2023, our self-insurance liabilities decreased due to a favorable $12.5 million adjustment after considering our updated actuarial estimates for projected incurred losses on past claims. Such estimates declined in 2023 due to favorable claim experience and loss mitigation efforts. |
Treasury Stock
Treasury Stock | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Treasury Stock | Note 19 — Treasury Stock On February 14, 2023, our Board of Directors authorized the repurchase of up to 7.5 million outstanding shares of common stock (the “Repurchase Plan”). Pursuant to the Repurchase Plan, the Company purchased 1.0 million shares of the Company’s common stock during the year ended December 31, 2023 for a total cost of $11.1 million inclusive of transaction costs. For the year ended December 31, 2022, the number of shares and value of shares repurchased were immaterial. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 20 — Subsequent Events The Company evaluated all subsequent events through the filing date of this Annual Report on Form 10-K. There were no events or transactions occurring during this subsequent reporting period which require recognition or additional disclosure in these financial statements. |
Schedule II - Valuation and Qua
Schedule II - Valuation and Qualifying Accounts and Reserves | 12 Months Ended |
Dec. 31, 2023 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |
Schedule II - Valuation and Qualifying Accounts and Reserves | Schedule II — Valuation and Qualifying Accounts and Reserves Description Beginning Balance Charged to Costs and Expenses Deductions Ending Balance (in thousands) 2023 Allowance for Doubtful Accounts $ 73,464 $ 35,604 $ 17,369 $ 91,699 2022 Allowance for Doubtful Accounts $ 65,584 $ 31,969 $ 24,088 $ 73,464 2021 Allowance for Doubtful Accounts $ 67,801 $ 10,483 $ 12,700 $ 65,584 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Pay vs Performance Disclosure | |||
Net income for the period | $ 38,386 | $ 34,243 | $ 48,543 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Dec. 31, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Description of Business and S_2
Description of Business and Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Nature of Operations | Healthcare Services Group, Inc. (the “Company”) provides management, administrative and operating expertise and services to the housekeeping, laundry, linen, facility maintenance and dietary service departments of the healthcare industry, including nursing homes, retirement complexes, rehabilitation centers and hospitals located throughout the United States. Although the Company does not directly participate in any government reimbursement programs, the Company’s customers receive government reimbursements related to Medicare and Medicaid. Therefore, they are directly affected by any legislation relating to Medicare and Medicaid reimbursement programs. The Company provides services primarily pursuant to full service agreements with its customers. In such agreements, the Company is responsible for the day-to-day management of employees located at the customers’ facilities, as well as for the provision of certain supplies. The Company also provides services on the basis of management-only agreements for a limited number of customers. In a management-only agreement, the Company provides management and supervisory services while the customer facility retains payroll responsibility for the non-supervisory staff. The agreements with customers typically provide for a renewable one year service term, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days. The Company is organized into two reportable segments: housekeeping, laundry, linen and other services (“Housekeeping”), and dietary department services (“Dietary”). Housekeeping consists of managing the customers’ housekeeping departments, which are principally responsible for the cleaning, disinfecting and sanitizing of resident rooms and common areas of a customer’s facility, as well as the laundering and processing of the bed linens, uniforms, resident personal clothing and other assorted linen items utilized at a customer facility. Dietary consists of managing the customers’ dietary departments, which are principally responsible for food purchasing, meal preparation and dietitian professional services, which includes the development of menus that meet residents’ dietary needs. |
Principles of Consolidation | The financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the SEC, specifically Regulation S-X and the instructions to Form 10-K. Unless otherwise indicated, all references to years are to the Company’s fiscal year, which ends on December 31. The accompanying Consolidated Financial Statements include the accounts of Healthcare Services Group, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. |
Use of Estimates in Financial Statements | In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes. |
Fair Value of Financial Instruments | The Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3) within the fair value hierarchy. Assets and liabilities are classified within the fair value hierarchy based on the lowest level (least observable) input that is significant to the measurement in its entirety. While unobservable inputs reflect the Company’s market assumptions, preference is given to observable inputs. These two types of inputs create the following fair value hierarchy: Level 1 – Quoted prices for identical instruments in active markets; Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable; and Level 3 – Significant inputs to the valuation model are unobservable |
Cash and Cash Equivalents | Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as short-term, highly liquid investments with a maturity of three months or less at time of purchase that are readily convertible into cash and have insignificant interest rate risk. The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. |
Investments in Marketable Securities | Marketable securities are defined as fixed income investments which are highly liquid and can be readily purchased or sold through established markets. As of December 31, 2023 and 2022, the Company had marketable securities of $93.1 million and $95.2 million, respectively, comprised primarily of tax-exempt municipal bonds. These investments are accounted for as available-for-sale securities and are reported at fair value on the Company's Consolidated Balance Sheets. For the year ended December 31, 2023, $1.6 million of unrealized gains related to these investments were recorded in Other comprehensive income (loss). For the years ended December 31, 2022 and 2021, $7.5 million and $1.6 million of unrealized losses related to these marketable securities were recorded in Other comprehensive income (loss), respectively. Unrealized gains and losses are recorded net of income taxes. These assets are held by the Company’s wholly-owned captive insurance company subsidiary as required by state insurance regulations. The Company’s investment policy is intended to manage the assets to achieve the goals of preserving principal, maintaining adequate liquidity at all times and maximizing returns subject to investment guidelines. The investment policy limits investment to certain types of instruments issued by institutions primarily with investment grade credit ratings and places restrictions on concentration by type and issuer. |
Accounts and Notes Receivable | Accounts and notes receivable consist of Housekeeping and Dietary segment trade receivables from contracts with customers. The Company’s payment terms with customers for services provided are defined within each customer’s service agreement and range from prepaid to 120 days. Accounts receivable are considered short term assets as the Company does not grant payment terms greater than one year. Accounts receivable initially are recorded at the transaction amount and are recorded after the Company has an unconditional right to payment where only the passage of time is required before payment is received. Each reporting period, the Company evaluates the collectability of outstanding receivable balances and records an allowance for doubtful accounts representing an estimate of current expected credit loss. Additions to the allowance for doubtful accounts are made by recording a charge to bad debt expense reported in costs of services provided. Notes receivable are initially recorded when accounts receivable are transferred into a promissory note and are recorded as an alternative to accounts receivable to memorialize an unqualified promise to pay a specific sum, typically with interest, in accordance with a defined payment schedule. The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however typically promissory notes mature over a 1 to 4 year period. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses. |
Allowance for Doubtful Accounts | Management utilizes financial modeling to determine an allowance that reflects its best estimate of the lifetime expected credit losses on accounts and notes receivable which is recorded to offset the receivables. Modeling is prepared after considering historical experience, current conditions, and reasonable and supportable economic forecasts to estimate lifetime expected credit losses. Accounts and notes receivable are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded as a reduction of bad debt expense when received. In making the Company’s credit evaluations, management considers the general collection risk associated with trends in the long-term care industry. The Company establishes credit limits through payment terms with customers, performs ongoing credit evaluations and monitors accounts on an aging schedule basis to minimize the risk of loss. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future industry trends change in such a manner as to negatively impact their cash flows. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s customers experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s consolidated results of operations and financial condition. The Company evaluates its accounts and notes receivable for expected credit losses quarterly. Accounts receivable are evaluated based on internally developed credit quality indicators derived from the aging of receivables. Notes receivable are evaluated based on internally developed credit quality indicators derived from management’s assessment of collection risk. The Company manages the accounts and notes receivable portfolios using a two-tiered approach by disaggregating standard notes receivables, which are invoices or promissory notes in good standing, from those who have been identified by management as having an elevated credit risk profile due to a triggering event such as bankruptcy. At the end of each period, the Company sets a reserve for expected credit losses on standard accounts and notes receivable based on the Company’s historical loss rates. Accounts and notes receivable with an elevated risk profile, which are from customers who have filed bankruptcy, are subject to collections activity or are slow payers that are experiencing financial difficulties, are aggregated and evaluated to determine the total reserve for the class of receivable. |
Inventories and Supplies | Inventories and supplies include housekeeping, linen and laundry supplies, as well as food provisions and supplies. Non-linen inventories and supplies are stated on a first-in, first-out (FIFO) basis, and reduced as deemed necessary to approximate the lower of cost or net realizable value. Linen supplies are amortized on a straight-line basis over their estimated useful life of 24 months. |
Revenue Recognition | The Company recognizes revenue from contracts with customers when or as the promised goods and services are provided to customers. Revenues are reported net of sales taxes that are collected from customers and remitted to taxing authorities. The amount of revenue recognized by the Company is based on the consideration to which the Company is entitled in exchange for providing the contracted goods and services and when it is probable that the Company will collect substantially all of such consideration. |
Leases | The Company records assets and liabilities on the Consolidated Balance Sheets to recognize the rights and obligations arising from leasing arrangements with contractual terms greater than 12 months. A leasing arrangement includes any contract which entitles the Company to the right of use of an identified tangible asset where there are no restrictions as to the direct of use of the asset, and the Company obtains substantially all of the economic benefits from the right of use. |
Property and Equipment, Net | Property and equipment, with the exception of those pertaining to leases, are stated at cost, net of accumulated depreciation. Additions, renewals and improvements are capitalized, while maintenance and repair costs are expensed when incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is included in Investment and other income (loss), net on the Consolidated Statements of Comprehensive Income. Depreciation is recorded using the straight-line method over the following estimated useful lives: Housekeeping and Dietary equipment — 3 to 5 years; computer hardware and software — 5 years; and other, consisting of furniture and fixtures, leasehold improvements and vehicles — 5 to 10 years. |
Income Taxes | The Company uses the asset and liability method of accounting for income taxes. Under this method, income tax expense or benefits are recognized for the amount of taxes payable or refundable for the current period. The Company accrues for probable tax obligations as required based on facts and circumstances in various regulatory environments. In addition, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. When appropriate, valuation allowances are recorded to reduce deferred tax assets to amounts for which realization is more likely than not. Uncertain income tax positions taken or expected to be taken in tax returns are reflected within the Company’s Consolidated Financial Statements based on a recognition and measurement process. The Company may from time to time be assessed interest or penalties by taxing jurisdictions, although any such assessments historically have been minimal and immaterial to its financial results. When the Company has received an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense. In addition, any interest or penalties relating to recognized uncertain tax positions would also be recorded in selling, general and administrative expense. |
Earnings per Common Share | Basic earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per common share is computed using the weighted-average number of common shares outstanding and dilutive common shares, such as those issuable upon exercise of stock options and upon the vesting of restricted stock and restricted stock units. |
Share-Based Compensation | The Company estimates the fair value of share-based awards on the date of grant using the Black-Scholes valuation model for stock options, using a Monte Carlo simulation for performance restricted stock units and using the share price on the date of grant for restricted stock units and deferred stock units. The value of the award is recognized ratably as an expense in the Company’s Consolidated Statements of Comprehensive Income over the requisite service periods, with adjustments made for forfeitures as they occur. |
Advertising Costs | Advertising costs are expensed when incurred. |
Impairment of Long-Lived Assets | The carrying amounts of long-lived assets are periodically reviewed to determine whether current events or circumstances warrant adjustment to such carrying amounts. Any impairment would be measured as the amount that the carrying value of such assets exceeds their fair value. Considerable management judgment is necessary to estimate the fair value of assets. Assets to be disposed of are carried at the lower of their financial statement carrying amount or fair value, less cost to sell. No impairment loss was recognized on the Company’s long-lived assets during the years ended December 31, 2023, 2022 or 2021. |
Identifiable Intangible Assets and Goodwill | Identifiable intangible assets are amortized on a straight-line basis over their respective lives. Goodwill represents the excess of cost over the fair value of net assets of acquired businesses. Management reviews the carrying value of goodwill annually during the fourth quarter to assess for impairment on a reporting unit basis or more often if events or circumstances indicate that the carrying value may exceed its estimated fair value. No impairment loss was recognized on the Company's intangible assets or goodwill during the years ended December 31, 2023, 2022 or 2021. |
Treasury Stock | Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid-in capital. |
Concentrations of Credit Risk | The Company’s financial instruments that are subject to credit risk are cash and cash equivalents, marketable securities, deferred compensation funding and accounts and notes receivable. At December 31, 2023 and 2022, the majority of the Company’s cash and cash equivalents and marketable securities were held in one large financial institution located in the United States. The Company’s marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could directly impact the governmental reimbursement programs in which the customers participate. As a result, the Company may not realize the full effects of such programs until these laws are fully implemented and governmental agencies issue applicable regulations or guidance. Although the Company negotiates the pricing and other terms for the majority of our purchases of food and dining supplies directly with national manufacturers, the Company procures more than 50% of these products and other items through Sysco Corporation (“Sysco”). Sysco is responsible for tracking the Company’s orders and delivering products to the Company’s specific locations. |
Significant Customer | For the years ended December 31, 2023, 2022 and 2021, Genesis Healthcare, Inc. (“Genesis”) accounted for $181.4 million or 10.9%, $169.1 million or 10.0% and $177.1 million or 10.8% of the Company’s consolidated revenues, respectively. As of December 31, 2023, the Company had outstanding accounts receivable and notes receivable of $61.8 million and $20.4 million, respectively, from Genesis. Although the Company expects to continue its relationship with Genesis, there can be no assurance thereof. Revenues generated from Genesis were included in both operating segments previously mentioned. Any extended discontinuance of revenues, or significant reduction, from this customer could, if not replaced, have a material impact on our operations. In addition, if Genesis fails to abide by current payment terms it could increase our accounts receivable balance and have a material adverse effect on our financial condition, results of operations, and cash flows. No other single customer or customer group represented more than 10% of consolidated revenues for the years ended December 31, 2023, 2022 and 2021. |
Reclassification | Certain prior period amounts have been reclassified to conform to current year presentation, including the presentation of deferred taxes in Note 12 — Income Taxes. There was no impact to the Company's consolidated financial statements as a result of this reclassification. |
Recent Accounting Pronouncements | In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which enhances effective tax rate reconciliation disclosure requirements and provides clarity to the disclosures of income taxes paid, income before taxes and provision for income taxes. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The amendments in this update should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company’s present or future consolidated financial statements. |
Employee Retention Credit | On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). One provision within the CARES Act provided an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable tax credit against the employer share of Social Security tax equal to 50% of the qualified wages paid to employees from March 13, 2020 through December 31, 2020. The ERC was subsequently expanded in 2021 for employers to claim a refundable tax credit for 70% of the qualified wages paid to employees from January 1, 2021 through September 30, 2021. The Company accounted for the ERC by analogy to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. During the quarter ended June 30, 2023, the Company filed a claim for the ERC for qualified wages paid in 2020 and 2021. Through February 16, 2024, the Company has yet to receive any refunds or receive any correspondence from the IRS regarding the ERC filing. The Company believes that there is not reasonable assurance that any receipt of credits will be obtained and therefore has not recognized any amounts related to the ERC in the accompanying consolidated financial statements. Should reasonable assurance over receipt of and compliance with terms of the ERC credits be obtained in future periods, the Company would recognize such amounts as an offset to expense within “Costs of services provided” in the Consolidated Statements of Comprehensive Income. In the event the Company obtains a refund in future periods, such refunds would be subject to IRS audit under the applicable statute of limitations. |
Segment Information | The Company’s accounting policies for the segments are generally the same as described in the Company’s significant accounting policies. Differences between the reportable segments’ operating results and other disclosed data and the information in the Consolidated Financial Statements relate primarily to corporate level transactions and recording of transactions at the reportable segment level using other than generally accepted accounting principles. There are certain inventories and supplies that are primarily expensed when incurred within the operating segments, while they are capitalized in the consolidated financial statements. In addition, most corporate expenses such as corporate salary and benefit costs, certain legal costs, bad debt expense, information technology costs, depreciation, amortization of finite-lived intangible assets, share based compensation costs and other corporate-specific costs, are not fully allocated to the operating segments. There are also allocations for workers’ compensation and general liability expense within the operating segments that differ from the actual expense recorded by the Company under U.S. GAAP. Segment amounts disclosed are prior to elimination entries made in consolidation. |
Revision of Prior Period Fina_2
Revision of Prior Period Financial Statements (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Changes and Error Corrections [Abstract] | |
Schedule of Effect of the Correction of Error | The effect of the correction of the error noted above on the Company’s Consolidated Balance Sheets as of December 31, 2022 is as follows: December 31, 2022 As reported Adjustment Revised (in thousands) Deferred tax asset $ 28,338 $ 2,502 $ 30,840 Total assets $ 718,334 $ 2,502 $ 720,836 Accrued payroll and related taxes $ 42,704 $ 10,395 $ 53,099 Total current liabilities $ 178,619 $ 10,395 $ 189,014 Retained earnings $ 154,495 $ (7,893) $ 146,602 Total liabilities and stockholders' equity $ 718,334 $ 2,502 $ 720,836 The effect of the correction of the error noted above on the Company’s Consolidated Statements of Comprehensive Income for the year ended December 31, 2022 is as follows: Year ended December 31, 2022 As reported Adjustment Revised (in thousands, except per share amounts) Costs of services provided $ 1,496,336 $ 529 $ 1,496,865 Income before income taxes $ 45,082 $ (529) $ 44,553 Income tax provision $ 10,452 $ (142) $ 10,310 Net income $ 34,630 $ (387) $ 34,243 Basic earnings per common share $ 0.47 $ (0.01) $ 0.46 Diluted earnings per common share $ 0.47 $ (0.01) $ 0.46 The effect of the correction of the errors noted above on the Company’s Consolidated Statements of Comprehensive Income for the year ended December 31, 2021 is as follows: Year ended December 31, 2021 As reported Adjustment Revised (in thousands, except per share amounts) Costs of services provided $ 1,415,082 $ (3,689) $ 1,411,393 Income before income taxes $ 61,823 $ 3,689 $ 65,512 Income tax provision $ 15,960 $ 1,009 $ 16,969 Net income $ 45,863 $ 2,680 $ 48,543 Basic earnings per common share $ 0.61 $ 0.04 $ 0.65 Diluted earnings per common share $ 0.61 $ 0.04 $ 0.65 |
Accounts and Notes Receivable (
Accounts and Notes Receivable (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Receivables [Abstract] | |
Schedule of Accounts and Notes Receivable | The Company’s accounts and notes receivable balances consisted of the following as of December 31, 2023 and 2022: December 31, 2023 December 31, 2022 (in thousands) Short-term Accounts and notes receivable $ 470,759 $ 406,969 Allowance for doubtful accounts (87,250) (70,192) Total net short-term accounts and notes receivable $ 383,509 $ 336,777 Long-term Notes receivable $ 29,281 $ 35,882 Allowance for doubtful accounts (4,449) (3,273) Total net long-term notes receivable $ 24,832 $ 32,609 Total net accounts and notes receivable $ 408,341 $ 369,386 |
Allowance for Doubtful Accoun_2
Allowance for Doubtful Accounts (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Receivables [Abstract] | |
Schedule of Notes Receivable Disaggregated by Vintage Year | The following tables present the Company’s two tiers of notes receivable for the years ended December 31, 2023 and 2022, respectively, further disaggregated by year of origination, as well as write-off activity: Notes Receivable as of December 31, 2023 Amortized Cost Basis by Origination Year 2023 2022 2021 2020 2019 Prior Total (in thousands) Notes Receivable Standard notes receivable $ 18,175 $ 25,505 $ 855 $ 1,529 $ 3 $ 21,033 $ 67,100 Elevated risk notes receivable $ — $ — $ 7,259 $ — $ — $ — $ 7,259 Current-period gross write-offs $ — $ 189 $ — $ — $ 50 $ 2,253 $ 2,492 Current-period recoveries — — — — — — — Current-period net write-offs $ — $ 189 $ — $ — $ 50 $ 2,253 $ 2,492 Notes Receivable as of December 31, 2022 Amortized Cost Basis by Origination Year 2022 2021 2020 2019 2018 Prior Total (in thousands) Notes Receivable Standard notes receivable $ 31,406 $ 10,887 $ 1,683 $ 208 $ 13 $ 21,982 $ 66,179 Elevated risk notes receivable $ — $ — $ — $ — $ — $ 1,223 $ 1,223 Current-period gross write-offs $ 1 $ — $ 51 $ 54 $ — $ 491 $ 597 Current-period recoveries — — — — — — — Current-period net write-offs $ 1 $ — $ 51 $ 54 $ — $ 491 $ 597 |
Schedule of Age Analysis of Past-Due Note Receivable | The following tables provide information as to the status of payment on the Company’s gross notes receivable which were past due as of December 31, 2023 and 2022, respectively: Age Analysis of Past-Due Notes Receivable as of December 31, 2023 0-90 Days 91 - 180 Days Greater than 181 Days Total (in thousands) Notes Receivable Standard notes receivable $ 3,851 $ 4,852 $ 6,914 $ 15,617 Elevated risk notes receivable 569 569 949 2,087 $ 4,420 $ 5,421 $ 7,863 $ 17,704 Age Analysis of Past-Due Notes Receivable as of December 31, 2022 0-90 Days 91 - 180 Days Greater than 181 Days Total (in thousands) Notes Receivable Standard notes receivable $ 894 $ 263 $ 3,330 $ 4,487 Elevated risk notes receivable — — 1,223 1,223 $ 894 $ 263 $ 4,553 $ 5,710 |
Schedule of Accounts Receivable, Allowance for Doubtful Accounts | The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the years ended December 31, 2023 and 2022, respectively: Allowance for doubtful accounts Portfolio Segment: December 31, Write-Offs 1 Bad Debt Expense December 31, (in thousands) Accounts receivable $ 66,601 $ (14,877) $ 29,095 $ 80,819 Notes receivable Standard notes receivable $ 6,052 $ (1,646) $ 1,719 $ 6,125 Elevated risk notes receivable 811 (846) 4,790 4,755 Total notes receivable $ 6,863 $ (2,492) $ 6,509 $ 10,880 Total accounts and notes receivable $ 73,464 $ (17,369) $ 35,604 $ 91,699 1. Write-offs are shown net of recoveries. During the year ended December 31, 2023, the Company collected $0.2 million of accounts receivables that were recovered subsequent to being written-off. Allowance for doubtful accounts Portfolio Segment: December 31, Write-Offs/Adjustments 1 Bad Debt Expense December 31, (in thousands) Accounts receivable $ 50,794 $ (16,825) $ 32,632 $ 66,601 Notes receivable Standard notes receivable $ 13,607 $ (6,783) $ (772) $ 6,052 Elevated risk notes receivable 1,183 (481) 109 811 Total notes receivable $ 14,790 $ (7,264) $ (663) $ 6,863 Total accounts and notes receivable $ 65,584 $ (24,089) $ 31,969 $ 73,464 1. |
Schedule of Allowance for Doubtful Accounts | The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the years ended December 31, 2023 and 2022, respectively: Allowance for doubtful accounts Portfolio Segment: December 31, Write-Offs 1 Bad Debt Expense December 31, (in thousands) Accounts receivable $ 66,601 $ (14,877) $ 29,095 $ 80,819 Notes receivable Standard notes receivable $ 6,052 $ (1,646) $ 1,719 $ 6,125 Elevated risk notes receivable 811 (846) 4,790 4,755 Total notes receivable $ 6,863 $ (2,492) $ 6,509 $ 10,880 Total accounts and notes receivable $ 73,464 $ (17,369) $ 35,604 $ 91,699 1. Write-offs are shown net of recoveries. During the year ended December 31, 2023, the Company collected $0.2 million of accounts receivables that were recovered subsequent to being written-off. Allowance for doubtful accounts Portfolio Segment: December 31, Write-Offs/Adjustments 1 Bad Debt Expense December 31, (in thousands) Accounts receivable $ 50,794 $ (16,825) $ 32,632 $ 66,601 Notes receivable Standard notes receivable $ 13,607 $ (6,783) $ (772) $ 6,052 Elevated risk notes receivable 1,183 (481) 109 811 Total notes receivable $ 14,790 $ (7,264) $ (663) $ 6,863 Total accounts and notes receivable $ 65,584 $ (24,089) $ 31,969 $ 73,464 1. |
Changes in Accumulated Other _2
Changes in Accumulated Other Comprehensive (Loss) Income by Component (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Schedule of Accumulated Other Comprehensive Income | The following tables provide a summary of the changes in accumulated other comprehensive income, net of taxes: Unrealized Gains and (Losses) on Available-for-Sale Securities 1 Year Ended December 31, 2023 2022 2021 (in thousands) Accumulated other comprehensive (loss) income — beginning balance $ (3,477) $ 4,000 $ 5,563 Other comprehensive income (loss) before reclassifications 1,624 (7,505) (1,522) Losses (gains) reclassified from other comprehensive income 2 9 28 (41) Net current period other comprehensive income (loss) 3 1,633 (7,477) (1,563) Accumulated other comprehensive (loss) income — ending balance $ (1,844) $ (3,477) $ 4,000 1. All amounts are net of tax. 2. Realized gains and losses were recorded pre-tax under “Investment and other income (loss), net” in the Consolidated Statements of Comprehensive Income. For the years ended December 31, 2023 and 2022, the Company recorded less than $0.1 million of realized losses from the sale of available-for-sale securities. For the year ended December 31, 2021, the Company recorded $0.1 million of realized gains from the sale of available-for-sale securities. Refer to Note 10 — Fair Value Measurements herein for further information. 3. For the year ended December 31, 2023, the change in other comprehensive (loss) income was net of a tax expense of $0.4 million. For the years ended December 31, 2022 and 2021, the changes in other comprehensive (loss) income were net of a tax benefit of $2.0 million and benefit of $0.4 million, respectively. |
Schedule of Reclassification out of Accumulated Other Comprehensive Income | Amounts Reclassified from Accumulated Other Comprehensive (Loss) Income 2023 2022 2021 (in thousands) Year Ended December 31, (Losses) gains from the sale of available-for-sale securities $ (12) $ (37) $ 55 Tax benefit (expense) 3 9 (14) Net (loss) gain reclassified from accumulated other comprehensive income $ (9) $ (28) $ 41 |
Property and Equipment (Tables)
Property and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment | The following table sets forth the amounts of property and equipment by each class of depreciable asset as of December 31, 2023 and December 31, 2022: December 31, 2023 December 31, 2022 (in thousands) Housekeeping and Dietary equipment $ 15,764 $ 13,585 Computer hardware and software 6,870 6,086 Operating lease — right-of-use assets 27,099 34,445 Other 1 1,070 1,055 Total property and equipment, at cost 50,803 55,171 Less accumulated depreciation 2 22,029 32,196 Total property and equipment, net $ 28,774 $ 22,975 1. Includes furniture and fixtures, leasehold improvements and autos and trucks. 2. Includes $9.4 million and $22.1 million related to accumulated depreciation on Operating lease – right-of-use assets as of December 31, 2023 and 2022, respectively. |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Schedule of Components of Lease Expense | Components of lease expense are presented below for the years ended December 31, 2023, 2022 and 2021. Year Ended December 31, 2023 2022 2021 (in thousands) Lease cost Operating lease cost $ 6,400 $ 5,673 $ 6,210 Short-term lease cost 1,037 1,265 747 Variable lease cost 1,952 857 973 Total lease cost $ 9,389 $ 7,795 $ 7,930 |
Schedule of Supplemental Information Required by ASC 842 | Supplemental information is presented below for the years ended December 31, 2023, 2022 and 2021. Year Ended December 31, 2023 2022 2021 (dollar amounts in thousands) Other information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 6,808 $ 6,385 $ 6,609 ROU Assets obtained in exchange for lease obligations $ 6,064 1,650 7,143 Weighted-average remaining lease term — operating leases 3.3 years 4.2 years 4.5 years Weighted-average discount rate — operating leases 6.6 % 4.4 % 4.2 % |
Schedule of Future Minimum Lease Payments | The following is a schedule by calendar year of future minimum lease payments under operating leases that have remaining terms as of December 31, 2023: Period/Year Operating Leases (in thousands) 2024 $ 7,365 2025 6,617 2026 3,768 2027 1,365 2028 1,389 Thereafter 116 Total minimum lease payments $ 20,620 Less: imputed lease payments 1,999 Present value of lease liabilities $ 18,621 |
Goodwill and Other Intangible_2
Goodwill and Other Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The following table sets forth the amounts of goodwill by reportable segment as of December 31, 2023 and 2022: December 31, 2023 December 31, 2022 (in thousands) Housekeeping $ 42,377 $ 42,377 Dietary 33,152 33,152 Total Goodwill $ 75,529 $ 75,529 |
Schedule of Intangible Assets | The following table sets forth the amounts of other intangible assets as of December 31, 2023 and 2022: December 31, 2023 December 31, 2022 Gross Amount Accumulated Amortization Net Amount Gross Amount Accumulated Amortization Net Amount (in thousands) Customer relationships $ 45,634 $ 35,718 $ 9,916 $ 45,634 $ 32,211 $ 13,423 Trade names 1,731 329 1,402 1,731 191 1,540 Patents 1,086 369 717 1,086 232 854 Non-compete agreements 233 141 92 233 104 129 Total other intangible assets $ 48,684 $ 36,557 $ 12,127 $ 48,684 $ 32,738 $ 15,946 |
Schedule of Estimated Amortization Expense For Intangibles Subject To Amortization | The following table sets forth the estimated amortization expense for intangibles subject to amortization for 2024, the following four fiscal years and thereafter: Period/Year Total Amortization Expense (in thousands) 2024 $ 2,685 2025 $ 2,685 2026 $ 2,666 2027 $ 1,196 2028 $ 613 Thereafter $ 2,282 Total $ 12,127 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value Measurements | The following tables provide fair value measurement information for the Company’s marketable securities and deferred compensation fund investments as of December 31, 2023 and December 31, 2022: As of December 31, 2023 Fair Value Measurement Using: Carrying Amount Total Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in thousands) Financial Assets: Marketable securities Municipal bonds — available-for-sale $ 93,131 $ 93,131 $ — $ 93,131 $ — Deferred compensation fund Money Market 1 $ 2,007 $ 2,007 $ — $ 2,007 $ — Commodities 298 298 298 — — Fixed Income 4,254 4,254 4,254 — — International 4,621 4,621 4,621 — — Large Cap Blend 5,053 5,053 5,053 — — Large Cap Growth 13,886 13,886 13,886 — — Large Cap Value 5,964 5,964 5,964 — — Mid Cap Blend 3,192 3,192 3,192 — — Real Estate 374 374 374 — — Small Cap Blend 2,664 2,664 2,664 — — Deferred compensation fund 2 $ 42,313 $ 42,313 $ 40,306 $ 2,007 $ — As of December 31, 2022 Fair Value Measurement Using: Carrying Total Fair Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in thousands) Financial Assets: Marketable securities Municipal bonds — available-for-sale $ 95,200 $ 95,200 $ — $ 95,200 $ — Deferred compensation fund Money Market 1 $ 2,420 $ 2,420 $ — $ 2,420 $ — Commodities 170 170 170 — — Fixed Income 3,571 3,571 3,571 — — International 4,093 4,093 4,093 — — Large Cap Blend 1,210 1,210 1,210 — — Large Cap Growth 11,064 11,064 11,064 — — Large Cap Value 6,133 6,133 6,133 — — Mid Cap Blend 2,667 2,667 2,667 — — Real Estate 359 359 359 — — Small Cap Blend 3,424 3,424 3,424 — — Deferred compensation fund 2 $ 35,111 $ 35,111 $ 32,691 $ 2,420 $ — 1. The fair value of the money market fund is based on the net asset value (“NAV”) of the shares held by the fund at the end of the period. The money market fund includes short-term United States dollar denominated money market instruments and the NAV is determined by the custodian of the fund. The money market fund can be redeemed at its NAV at the measurement date as there are no significant restrictions on the ability to sell this investment. 2. The deferred compensation fund carrying amounts and total fair value amounts as of December 31, 2023 and 2022 are inclusive of $1.5 million and $1.6 million of holdings expected to be paid to former employees within the next twelve months and were recorded under Prepaid expenses and other assets in the Company’s Consolidated Balance Sheets. |
Schedule of Marketable Debt Securities | Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Impairments (in thousands) December 31, 2023 Type of security: Municipal bonds — available-for-sale $ 95,466 $ 387 $ (2,722) $ 93,131 $ — Total debt securities $ 95,466 $ 387 $ (2,722) $ 93,131 $ — December 31, 2022 Type of security: Municipal bonds — available-for-sale $ 99,601 $ 229 $ (4,630) $ 95,200 $ — Total debt securities $ 99,601 $ 229 $ (4,630) $ 95,200 $ — |
Schedule of Contractual Maturities of Available for Sale Investments | The following table summarizes the contractual maturities of debt securities held at December 31, 2023 and December 31, 2022, which are classified as marketable securities in the Company’s Consolidated Balance Sheets: Municipal Bonds — Available-for-Sale Contractual maturity: December 31, 2023 December 31, 2022 (in thousands) Maturing in one year or less $ 6,324 $ 2,798 Maturing in second year through fifth year 34,939 35,068 Maturing in sixth year through tenth year 39,309 38,575 Maturing after ten years 12,559 18,759 Total debt securities $ 93,131 $ 95,200 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Stock-based Compensation Expense | The components of the Company’s share-based compensation expense for the years ended December 31, 2023, 2022 and 2021 are as follows: Year Ended December 31, 2023 2022 2021 (in thousands) Stock options $ 969 $ 1,253 $ 1,832 Restricted stock, restricted stock units and deferred stock units 6,657 6,972 6,367 Performance stock units 1,210 819 401 Employee Stock Purchase Plan 149 170 227 Total pre-tax share-based compensation expense charged against income $ 8,985 $ 9,214 $ 8,827 Total recognized tax deficiency related to share-based compensation $ (773) $ (783) $ (217) The following table summarizes the components of share-based compensation expense included within the Consolidated Statements of Comprehensive Income for the years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 (in thousands) Selling, general & administrative expense $ 8,942 $ 9,160 $ 8,767 Costs of services provided 43 54 60 Total $ 8,985 $ 9,214 $ 8,827 |
Schedule of Other Information of Stock Option Plans | A summary of stock options outstanding under the Amended 2020 Plan and the 2012 Plan as of December 31, 2023, December 31, 2022 and changes during the year ended December 31, 2023 are as follows: Stock Options Outstanding Number of Shares Weighted Average Exercise Price (in thousands) December 31, 2022 2,375 $ 31.56 Granted 207 $ 13.72 Exercised — $ — Forfeited — $ — Expired (144) $ 24.99 December 31, 2023 2,438 $ 30.43 |
Schedule of Assumption For Fair Value of Options Granted | The fair value of stock option awards granted in 2023, 2022 and 2021 were estimated on the dates of grant using the Black-Scholes option valuation model with the following assumptions: Year Ended December 31, 2023 2022 2021 Risk-free interest rate 4.0 % 1.5 % 0.6 % Weighted average expected life 6.9 years 6.7 years 6.6 years Expected volatility 39.5 % 36.6 % 34.7 % Dividend yield — % 4.6 % 2.9 % |
Schedule of Information of Stock Options Outstanding | The following table summarizes other information about the stock options at December 31, 2023: December 31, 2023 (amounts in thousands, except per share data) Outstanding: Aggregate intrinsic value $ — Weighted average remaining contractual life 4.5 years Exercisable: Number of options 1,702 Weighted average exercise price $ 34.72 Aggregate intrinsic value $ — Weighted average remaining contractual life 2.6 years |
Schedule of Outstanding Restricted Stock Units and Restricted Stock | A summary of the outstanding restricted stock units as of December 31, 2023, December 31, 2022 and changes during the year ended December 31, 2023 is as follows: Restricted Stock Units Number Weighted Average Grant Date Fair Value (in thousands) December 31, 2022 825 $ 24.37 Granted 536 $ 13.72 Vested (237) $ 27.82 Forfeited (22) $ 18.76 December 31, 2023 1,102 $ 18.57 |
Schedule of Weighted Average Grant-Date Fair Values and Intrinsic Values of Options Vested | The weighted average grant-date fair values and total fair values of restricted stock units vested during 2023, 2022 and 2021 were as follows: Year Ended December 31, 2023 2022 2021 (in thousands, except per share data) Weighted average grant-date fair value of restricted stock units granted $ 13.72 $ 18.06 $ 28.53 Total fair value of restricted stock units and restricted shares vested $ 2,991 $ 3,307 $ 4,185 |
Schedule of Outstanding Performance Stock Units | A summary of the outstanding PSUs as of December 31, 2023, December 31, 2022 and changes during the year ended December 31, 2023 is as follows: Performance Stock Units Number Weighted Average Grant Date Fair Value (in thousands) December 31, 2022 95 $ 26.01 Granted 80 $ 16.20 Vested — $ — Forfeited — $ — December 31, 2023 175 $ 21.52 |
Schedule of ESPP Annual Offerings | The following table summarizes information about the Company’s ESPP annual offerings for the years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 (in thousands, except per share data) Common shares purchased 95 95 85 Per common share purchase price $ 8.81 $ 10.20 $ 15.12 |
Schedule of Options Granted Estimated Expense Valuation Assumptions | The expense associated with the options granted under the ESPP during the year ended December 31, 2023 and 2022 was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions: Year Ended December 31, 2023 2022 Risk-free interest rate 4.8% 0.4% Weighted average expected life (years) 1.0 1.0 Expected volatility 42.9% 36.9% Dividend yield 7.1% 4.7% |
Schedule of Information Of SERP | The following table summarizes information about the SERP during the plan years ended December 31, 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 (in thousands) SERP expense 1 $ 533 $ 486 $ 531 Treasury shares issued to fund SERP expense 2 50 40 30 Year end SERP trust account balance 3 $ 42,313 $ 35,111 $ 59,086 Unrealized gain (loss) recorded in SERP liability account $ 6,684 $ (9,178) $ 6,676 1. Both the SERP match and the deferrals are included in the selling, general and administrative caption in the Consolidated Statements of Comprehensive Income. 2. Shares related to the SERP match for each year are funded at the beginning of the subsequent year. 3. SERP trust account investments are recorded at their fair value which is based on quoted market prices. Differences between such amounts in the table above and the deferred compensation funding asset reported on the Company’s Consolidated Balance Sheets represent the value of Company common stock held in the Plan participants’ trust accounts and reported by the Company as treasury stock in the Company’s Consolidated Balance Sheets. |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Provision for Income Taxes | The following table summarizes the provision for income taxes: Year Ended December 31, 2023 2022 2021 (amounts in thousands) Current: Federal $ 13,728 $ 3,022 $ 9,120 State 5,762 2,381 3,766 $ 19,490 $ 5,403 $ 12,886 Deferred: Federal $ (4,183) $ 4,163 $ 3,127 State (637) 744 956 $ (4,820) $ 4,907 $ 4,083 Tax provision $ 14,670 $ 10,310 $ 16,969 |
Schedule of Significant Components of Federal and State Deferred Tax Assets and Liabilities | Significant components of the Company’s federal and state deferred tax asset and liability balances were as follows: Year Ended December 31, 2023 2022 (in thousands) Deferred tax assets: Allowance for doubtful accounts $ 22,788 $ 18,139 Deferred compensation 9,048 8,686 Accrued insurance claims 5,580 5,609 Non-deductible reserves 169 256 Lease liabilities 4,765 5,709 Share based compensation 2,988 2,142 Other 2,418 2,848 $ 47,756 $ 43,389 Deferred tax liabilities: Expensing of housekeeping supplies $ (2,351) $ (2,510) Amortization of goodwill and intangibles (3,000) (2,389) Depreciation of property and equipment (1,688) (1,769) Lease right-of-use assets (4,571) (5,482) Other (920) (399) $ (12,530) $ (12,549) Net deferred tax assets $ 35,226 $ 30,840 |
Schedule of Reconciliation of The Provision for Income Taxes | The table below provides a reconciliation between the tax expense computed by applying the statutory federal income tax rate to income before income taxes and the provision for income taxes: Year Ended December 31, 2023 2022 2021 (in thousands) Income tax expense computed at statutory rate $ 11,182 $ 9,356 $ 13,758 Increases (decreases) resulting from: State income taxes, net of federal tax benefit 4,153 2,594 4,165 Federal jobs credits (2,014) (2,571) (3,177) Tax exempt interest (348) (308) (324) Share-based compensation 1,610 1,250 1,072 Fines and penalties 55 4 1,294 Other, net 32 (15) 181 Income tax expense $ 14,670 $ 10,310 $ 16,969 |
Segment Information (Tables)
Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Segment Information | Year Ended December 31, 2023 2022 2021 (in thousands) Revenues 1 Housekeeping $ 766,651 $ 795,687 $ 821,329 Dietary 904,738 894,489 820,630 Total $ 1,671,389 $ 1,690,176 $ 1,641,959 Income before income taxes Housekeeping $ 61,311 $ 73,096 $ 79,380 Dietary 43,547 29,065 45,758 Corporate 2 (51,802) (57,608) (59,626) Total $ 53,056 $ 44,553 $ 65,512 Depreciation and amortization Housekeeping $ 4,380 $ 5,491 $ 5,399 Dietary 3,001 3,075 2,611 Corporate 6,963 6,750 6,657 Consolidated $ 14,344 $ 15,316 $ 14,667 Total assets Housekeeping $ 253,729 $ 250,444 $ 225,531 Dietary 291,550 263,126 221,911 Corporate 3 245,373 207,266 332,447 Consolidated $ 790,652 $ 720,836 $ 779,889 Capital expenditures Housekeeping $ 4,684 $ 4,412 $ 5,005 Dietary 494 499 451 Corporate 228 299 231 Consolidated $ 5,406 $ 5,210 $ 5,687 1. For the years ended December 31, 2023 and 2022, both the Housekeeping and Dietary segments earned revenue from several significant customers, although Genesis was the only customer to contribute more than 10% of consolidated revenue. For the years ended December 31, 2023, 2022 and 2021, Genesis accounted for $181.4 million or 10.9%, $169.1 million or 10.0% and $177.1 million or 10.8% of the Company’s consolidated revenues, respectively. 2. Primarily represents corporate office costs and related overhead, recording of certain inventories and supplies and workers compensation costs at the reportable segment level which use accounting methods that differ from those used at the corporate level, as well as consolidated subsidiaries’ operating expenses that are not allocated to the reportable segments, net of investment and other income and interest expense. 3. Primarily consists of cash and cash equivalents, marketable securities, deferred income taxes and other current and noncurrent assets. |
Earnings Per Common Share (Tabl
Earnings Per Common Share (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Weighted Average Number of Shares | The table below reconciles the weighted-average basic and diluted common shares outstanding for 2023, 2022 and 2021: Year Ended December 31, 2023 2022 2021 Numerator for basic and diluted earnings per share: Net income $ 38,386 $ 34,243 $ 48,543 Denominator: Weighted average number of common shares outstanding - basic 74,288 74,336 74,816 Effect of dilutive securities 1 52 15 146 Weighted average number of common shares outstanding - diluted 74,340 74,351 74,962 Basic earnings per share: $ 0.52 $ 0.46 $ 0.65 Diluted earnings per share: $ 0.52 $ 0.46 $ 0.65 1. |
Schedule Anti-dilutive Outstanding Equity Awards Under Share Based Compensation Plans | Anti-dilutive outstanding equity awards under share-based compensation plans were as follows: Year Ended December 31, 2023 2022 2021 (in thousands) Anti-dilutive equity awards 3,228 3,203 1,980 |
Description of Business and S_3
Description of Business and Significant Accounting Policies - Additional Information (Details) | 12 Months Ended | ||
Dec. 31, 2023 USD ($) segment institution | Dec. 31, 2022 USD ($) institution | Dec. 31, 2021 USD ($) | |
Schedule of Accounting Policies [Line Items] | |||
Renewal term | 1 year | ||
Number of reportable segments | segment | 2 | ||
Marketable securities | $ 93,131,000 | $ 95,200,000 | |
Unrealized gains (losses) from marketable securities | $ 1,600,000 | (7,500,000) | $ (1,600,000) |
Payment terms | The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however typically promissory notes mature over a 1 to 4 year period. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses. | ||
Amortization period of inventories and supplies | 24 months | ||
Depreciation | $ 10,500,000 | 10,500,000 | 10,300,000 |
Impairment of long-lived assets | 0 | 0 | 0 |
Goodwill and intangible asset impairment | $ 0 | $ 0 | 0 |
Number of financial institutions holding cash and cash equivalents and marketable securities | institution | 1 | 1 | |
Revenues | $ 1,671,389,000 | $ 1,690,176,000 | $ 1,641,959,000 |
Accounts receivable | 383,509,000 | 336,777,000 | |
Notes receivable | 24,832,000 | $ 32,609,000 | |
Genesis | |||
Schedule of Accounting Policies [Line Items] | |||
Accounts receivable | 61,800,000 | ||
Notes receivable | $ 20,400,000 | ||
Vendor | Products and other items | Sysco | |||
Schedule of Accounting Policies [Line Items] | |||
Concentration percentage | 50% | ||
Significant Customers | Consolidated revenues | Genesis | |||
Schedule of Accounting Policies [Line Items] | |||
Concentration percentage | 10.90% | 10% | 10.80% |
Revenues | $ 181,400,000 | $ 169,100,000 | $ 177,100,000 |
Computer hardware and software | |||
Schedule of Accounting Policies [Line Items] | |||
Property plant and equipment, useful life | 5 years | ||
Minimum | |||
Schedule of Accounting Policies [Line Items] | |||
Cancellation notice period | 30 days | ||
Initial period preceding cancellation notice | 60 days | ||
Minimum | Housekeeping and Dietary equipment | |||
Schedule of Accounting Policies [Line Items] | |||
Property plant and equipment, useful life | 3 years | ||
Minimum | Vehicles | |||
Schedule of Accounting Policies [Line Items] | |||
Property plant and equipment, useful life | 5 years | ||
Maximum | |||
Schedule of Accounting Policies [Line Items] | |||
Cancellation notice period | 90 days | ||
Initial period preceding cancellation notice | 120 days | ||
Maximum | Housekeeping and Dietary equipment | |||
Schedule of Accounting Policies [Line Items] | |||
Property plant and equipment, useful life | 5 years | ||
Maximum | Vehicles | |||
Schedule of Accounting Policies [Line Items] | |||
Property plant and equipment, useful life | 10 years |
Revision of Prior Period Fina_3
Revision of Prior Period Financial Statements - Schedule of Correction of Error Statements (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Deferred tax assets | $ 35,226 | $ 30,840 | ||
Total assets | 790,652 | 720,836 | $ 779,889 | |
Accrued payroll and related taxes | 56,142 | 53,099 | ||
Total current liabilities | 216,928 | 189,014 | ||
Retained earnings | 185,010 | 146,602 | ||
Total liabilities and stockholders' equity | 790,652 | 720,836 | ||
Costs of services provided | 1,456,643 | 1,496,865 | 1,411,393 | |
Income before income taxes | 53,056 | 44,553 | 65,512 | |
Income tax provision | 14,670 | 10,310 | 16,969 | |
Net income | $ 38,386 | $ 34,243 | $ 48,543 | |
Basic earnings per common share (in dollars per share) | $ 0.52 | $ 0.46 | $ 0.65 | |
Diluted earnings per common share (in dollars per share) | $ 0.52 | $ 0.46 | $ 0.65 | |
Reduction in retained earnings | $ (185,010) | $ (146,602) | ||
As reported | ||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Deferred tax assets | 28,338 | |||
Total assets | 718,334 | |||
Accrued payroll and related taxes | 42,704 | |||
Total current liabilities | 178,619 | |||
Retained earnings | 154,495 | |||
Total liabilities and stockholders' equity | 718,334 | |||
Costs of services provided | 1,496,336 | $ 1,415,082 | ||
Income before income taxes | 45,082 | 61,823 | ||
Income tax provision | 10,452 | 15,960 | ||
Net income | $ 34,630 | $ 45,863 | ||
Basic earnings per common share (in dollars per share) | $ 0.47 | $ 0.61 | ||
Diluted earnings per common share (in dollars per share) | $ 0.47 | $ 0.61 | ||
Reduction in retained earnings | $ (154,495) | |||
Adjustment | ||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||
Deferred tax assets | 2,502 | |||
Total assets | 2,502 | |||
Accrued payroll and related taxes | 10,395 | |||
Total current liabilities | 10,395 | |||
Retained earnings | (7,893) | $ (7,500) | $ (10,200) | |
Total liabilities and stockholders' equity | 2,502 | |||
Costs of services provided | 529 | (3,689) | ||
Income before income taxes | (529) | 3,689 | ||
Income tax provision | (142) | 1,009 | ||
Net income | $ (387) | $ 2,680 | ||
Basic earnings per common share (in dollars per share) | $ (0.01) | $ 0.04 | ||
Diluted earnings per common share (in dollars per share) | $ (0.01) | $ 0.04 | ||
Reduction in retained earnings | $ 7,893 | $ 7,500 | $ 10,200 |
Revenue - Additional Informatio
Revenue - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disaggregation of Revenue [Line Items] | |||
Revenue | $ 1,671,389 | $ 1,690,176 | $ 1,641,959 |
Renewal term | 1 year | ||
Reduction in revenue | $ 13,800 | 10,000 | |
Revenue recognized | $ 1,800 | ||
Description of timing | The Company’s contracts with customers typically provide for an initial term of one year, with renewable one year service terms, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days. | ||
Transferred at point in time | |||
Disaggregation of Revenue [Line Items] | |||
Contract liabilities | $ 100 | 300 | |
Transferred over time | |||
Disaggregation of Revenue [Line Items] | |||
Contract liabilities | $ 3,200 | 3,100 | |
Minimum | |||
Disaggregation of Revenue [Line Items] | |||
Cancellation notice period | 30 days | ||
Initial period preceding cancellation notice | 60 days | ||
Maximum | |||
Disaggregation of Revenue [Line Items] | |||
Cancellation notice period | 90 days | ||
Initial period preceding cancellation notice | 120 days | ||
Housekeeping | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | $ 766,700 | 795,700 | 821,300 |
Dietary | |||
Disaggregation of Revenue [Line Items] | |||
Revenue | $ 904,700 | $ 894,500 | $ 820,600 |
Revenue - Remaining Performance
Revenue - Remaining Performance Obligation (Details) $ in Millions | Dec. 31, 2023 USD ($) |
Revenue from Contract with Customer [Abstract] | |
Remaining performance obligation | $ 13.7 |
Remaining performance obligation percent | 100% |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Remaining performance obligations period | 12 months |
Accounts and Notes Receivable -
Accounts and Notes Receivable - Schedule of Accounts and Notes Receivable (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Short-term | ||
Accounts and notes receivable | $ 470,759 | $ 406,969 |
Allowance for doubtful accounts | (87,250) | (70,192) |
Total net short-term accounts and notes receivable | 383,509 | 336,777 |
Long-term | ||
Notes receivable | 29,281 | 35,882 |
Allowance for doubtful accounts | (4,449) | (3,273) |
Total net long-term notes receivable | 24,832 | 32,609 |
Total net accounts and notes receivable | $ 408,341 | $ 369,386 |
Allowance for Doubtful Accoun_3
Allowance for Doubtful Accounts - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Receivables [Abstract] | |||
Interest income | $ 2.8 | $ 1.1 | $ 1.2 |
Allowance for Doubtful Accoun_4
Allowance for Doubtful Accounts - Notes Receivable Disaggregated by Vintage Year (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Current-period gross write-offs | ||
Current fiscal year | $ 0 | $ 1 |
Year two | 189 | 0 |
Year three | 0 | 51 |
Year four | 0 | 54 |
Year five | 50 | 0 |
Prior | 2,253 | 491 |
Current-period gross write-offs | 2,492 | 597 |
Current-period recoveries | ||
Current fiscal year | 0 | 0 |
Year two | 0 | 0 |
Year three | 0 | 0 |
Year four | 0 | 0 |
Year five | 0 | 0 |
Prior | 0 | 0 |
Current-period recoveries | 0 | 0 |
Current-period net write-offs | ||
Current fiscal year | 0 | 1 |
Year two | 189 | 0 |
Year three | 0 | 51 |
Year four | 0 | 54 |
Year five | 50 | 0 |
Prior | 2,253 | 491 |
Current-period net write-offs | 2,492 | 597 |
Standard notes receivable | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Current fiscal year | 18,175 | 31,406 |
Year two | 25,505 | 10,887 |
Year three | 855 | 1,683 |
Year four | 1,529 | 208 |
Year five | 3 | 13 |
Prior | 21,033 | 21,982 |
Total | 67,100 | 66,179 |
Current-period net write-offs | ||
Current-period net write-offs | 1,646 | |
Elevated risk notes receivable | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Current fiscal year | 0 | 0 |
Year two | 0 | 0 |
Year three | 7,259 | 0 |
Year four | 0 | 0 |
Year five | 0 | 0 |
Prior | 0 | 1,223 |
Total | 7,259 | $ 1,223 |
Current-period net write-offs | ||
Current-period net write-offs | $ 846 |
Allowance for Doubtful Accoun_5
Allowance for Doubtful Accounts - Age Analysis of Past-Due Note Receivable (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Total | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | $ 17,704 | $ 5,710 |
0-90 Days | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 4,420 | 894 |
91 - 180 Days | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 5,421 | 263 |
Greater than 181 Days | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 7,863 | 4,553 |
Standard notes receivable | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 67,100 | 66,179 |
Standard notes receivable | Total | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 15,617 | 4,487 |
Standard notes receivable | 0-90 Days | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 3,851 | 894 |
Standard notes receivable | 91 - 180 Days | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 4,852 | 263 |
Standard notes receivable | Greater than 181 Days | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 6,914 | 3,330 |
Elevated risk notes receivable | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 7,259 | 1,223 |
Elevated risk notes receivable | Total | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 2,087 | 1,223 |
Elevated risk notes receivable | 0-90 Days | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 569 | 0 |
Elevated risk notes receivable | 91 - 180 Days | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | 569 | 0 |
Elevated risk notes receivable | Greater than 181 Days | ||
Financing Receivable, Past Due [Line Items] | ||
Notes Receivable | $ 949 | $ 1,223 |
Allowance for Doubtful Accoun_6
Allowance for Doubtful Accounts - Allowance for doubtful accounts (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Accounts receivable | |||
Accounts receivable, Allowance for doubtful accounts, beginning balance | $ 66,601 | $ 50,794 | |
Write-Offs/Adjustments | (14,877) | (16,825) | |
Bad Debt Expense | 29,095 | 32,632 | |
Accounts receivable, Allowance for doubtful accounts, ending balance | 80,819 | 66,601 | $ 50,794 |
Notes receivable | |||
Financing receivable reserves, beginning balance | 6,863 | 14,790 | |
Write-Offs/Adjustments | (2,492) | (597) | |
Write-Offs/Adjustments | (7,264) | ||
Bad Debt Expense | 6,509 | (663) | |
Financing receivable reserves, ending balance | 10,880 | 6,863 | 14,790 |
Accounts and Financing Receivable | |||
Total accounts and notes receivable, beginning balance | 73,464 | 65,584 | |
Write-Offs/Adjustments | (17,369) | (24,089) | |
Bad Debt Expense | 35,604 | 31,969 | 10,483 |
Total accounts and notes receivable, ending balance | 91,699 | 73,464 | 65,584 |
Accounts receivable recovered after write off | 200 | 300 | |
Reduction of allowance for doubtful accounts | 8,000 | ||
Standard notes receivable | |||
Notes receivable | |||
Financing receivable reserves, beginning balance | 6,052 | 13,607 | |
Write-Offs/Adjustments | (1,646) | ||
Write-Offs/Adjustments | (6,783) | ||
Bad Debt Expense | 1,719 | (772) | |
Financing receivable reserves, ending balance | 6,125 | 6,052 | 13,607 |
Elevated risk notes receivable | |||
Notes receivable | |||
Financing receivable reserves, beginning balance | 811 | 1,183 | |
Write-Offs/Adjustments | (846) | ||
Write-Offs/Adjustments | (481) | ||
Bad Debt Expense | 4,790 | 109 | |
Financing receivable reserves, ending balance | $ 4,755 | $ 811 | $ 1,183 |
Changes in Accumulated Other _3
Changes in Accumulated Other Comprehensive (Loss) Income by Component - Summary of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Accumulated other comprehensive income | |||
Beginning balance | $ 418,279 | $ 445,171 | $ 470,276 |
Other comprehensive income (loss) before reclassifications | 1,624 | (7,505) | (1,522) |
Losses (gains) reclassified from other comprehensive income | 9 | 28 | (41) |
Net current period other comprehensive (loss) income | 1,633 | (7,477) | (1,563) |
Ending balance | 456,616 | 418,279 | 445,171 |
Realized loss | 100 | 100 | |
Realized gain | 100 | ||
Changes in other comprehensive (loss) income, tax benefit (expense) | (400) | 2,000 | 400 |
Accumulated Other Comprehensive Income (Loss), net of Taxes | |||
Accumulated other comprehensive income | |||
Beginning balance | (3,477) | 4,000 | 5,563 |
Ending balance | $ (1,844) | $ (3,477) | $ 4,000 |
Changes in Accumulated Other _4
Changes in Accumulated Other Comprehensive (Loss) Income by Component - Reclassification Adjustments (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | |||
(Losses) gains from the sale of available-for-sale securities | $ 12,938 | $ (5,427) | $ 9,439 |
Tax benefit (expense) | (14,670) | (10,310) | (16,969) |
Net (loss) gain reclassified from accumulated other comprehensive income | 38,386 | 34,243 | 48,543 |
Amounts Reclassified from Accumulated Other Comprehensive (Loss) Income | |||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | |||
Net (loss) gain reclassified from accumulated other comprehensive income | (9) | (28) | 41 |
Realized Gains (Losses) on Sale of Available-for-sale Securities | Amounts Reclassified from Accumulated Other Comprehensive (Loss) Income | |||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | |||
(Losses) gains from the sale of available-for-sale securities | (12) | (37) | 55 |
Tax benefit (expense) | $ 3 | $ 9 | $ (14) |
Property and Equipment (Details
Property and Equipment (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | |||
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] | Property and equipment, net | Property and equipment, net | |
Operating lease — right-of-use assets | $ 27,099 | $ 34,445 | |
Total property and equipment, at cost | 50,803 | 55,171 | |
Less accumulated depreciation | 22,029 | 32,196 | |
Property and equipment, net | 28,774 | 22,975 | |
Accumulated depreciation on operating lease right-of-use assets | 9,400 | 22,100 | |
Depreciation | 10,500 | 10,500 | $ 10,300 |
ROU Assets depreciation | 6,400 | 6,100 | $ 6,400 |
Housekeeping and Dietary equipment | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 15,764 | 13,585 | |
Computer hardware and software | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | 6,870 | 6,086 | |
Other | |||
Property, Plant and Equipment [Line Items] | |||
Property and equipment, gross | $ 1,070 | $ 1,055 |
Leases - Additional Information
Leases - Additional Information (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Lessee, Lease, Description [Line Items] | ||
Termination option | 1 year | |
Other Accrued Liability, Current, Statement of Financial Position [Extensible List] | Other Accrued Liabilities, Current | Other Accrued Liabilities, Current |
Short-term lease obligation | $ 7.4 | $ 5.3 |
ROU Assets and Lease Liabilities reduction due to cancellation | $ 2.7 | $ 1.7 |
Minimum | ||
Lessee, Lease, Description [Line Items] | ||
Remaining lease term | 1 year | |
Extension option | 1 year | |
Maximum | ||
Lessee, Lease, Description [Line Items] | ||
Remaining lease term | 5 years | |
Extension option | 5 years |
Leases - Components of Lease Ex
Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Lease cost | |||
Operating lease cost | $ 6,400 | $ 5,673 | $ 6,210 |
Short-term lease cost | 1,037 | 1,265 | 747 |
Variable lease cost | 1,952 | 857 | 973 |
Total lease cost | 9,389 | 7,795 | 7,930 |
Cash paid for amounts included in the measurement of lease liabilities | |||
Operating cash flows from operating leases | 6,808 | 6,385 | 6,609 |
ROU Assets obtained in exchange for lease obligations | $ 6,064 | $ 1,650 | $ 7,143 |
Weighted-average remaining lease term — operating leases | 3 years 3 months 18 days | 4 years 2 months 12 days | 4 years 6 months |
Weighted-average discount rate — operating leases | 6.60% | 4.40% | 4.20% |
Leases - Schedule of Future Min
Leases - Schedule of Future Minimum Lease Payments (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
Leases [Abstract] | |
2024 | $ 7,365 |
2025 | 6,617 |
2026 | 3,768 |
2027 | 1,365 |
2028 | 1,389 |
Thereafter | 116 |
Total minimum lease payments | 20,620 |
Less: imputed lease payments | 1,999 |
Present value of lease liabilities | $ 18,621 |
Goodwill and Other Intangible_3
Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | |||
Impairment of goodwill | $ 0 | ||
Amortization of intangible assets | $ 3,800,000 | $ 4,900,000 | $ 4,400,000 |
Customer relationships | |||
Finite-Lived Intangible Assets [Line Items] | |||
Weighted average useful life (in years) | 10 years | ||
Trade names | |||
Finite-Lived Intangible Assets [Line Items] | |||
Weighted average useful life (in years) | 13 years | ||
Patents | |||
Finite-Lived Intangible Assets [Line Items] | |||
Weighted average useful life (in years) | 8 years | ||
Non-compete agreements | |||
Finite-Lived Intangible Assets [Line Items] | |||
Weighted average useful life (in years) | 4 years |
Goodwill and Other Intangible_4
Goodwill and Other Intangible Assets - Goodwill by Reportable Segment (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Goodwill [Line Items] | ||
Goodwill | $ 75,529 | $ 75,529 |
Housekeeping | ||
Goodwill [Line Items] | ||
Goodwill | 42,377 | 42,377 |
Dietary | ||
Goodwill [Line Items] | ||
Goodwill | $ 33,152 | $ 33,152 |
Goodwill and Other Intangible_5
Goodwill and Other Intangible Assets - Other Intangible Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amount | $ 48,684 | $ 48,684 |
Accumulated Amortization | 36,557 | 32,738 |
Total | 12,127 | 15,946 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amount | 45,634 | 45,634 |
Accumulated Amortization | 35,718 | 32,211 |
Total | 9,916 | 13,423 |
Trade names | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amount | 1,731 | 1,731 |
Accumulated Amortization | 329 | 191 |
Total | 1,402 | 1,540 |
Patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amount | 1,086 | 1,086 |
Accumulated Amortization | 369 | 232 |
Total | 717 | 854 |
Non-compete agreements | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Amount | 233 | 233 |
Accumulated Amortization | 141 | 104 |
Total | $ 92 | $ 129 |
Goodwill and Other Intangible_6
Goodwill and Other Intangible Assets - Estimated Amortization Expense For Intangibles Subject To Amortization (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2024 | $ 2,685 | |
2025 | 2,685 | |
2026 | 2,666 | |
2027 | 1,196 | |
2028 | 613 | |
Thereafter | 2,282 | |
Total | $ 12,127 | $ 15,946 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes | $ 1,600 | $ (7,500) | $ (1,600) |
Proceeds from available for sale municipal bonds | 1,992 | 10,386 | 26,697 |
Realized loss | 100 | 100 | |
Realized gain | 100 | ||
Realized gains | 1,100 | 2,400 | 100 |
Unrealized gains related to equity securities | 6,600 | 6,500 | |
Unrealized losses related to equity securities | 9,300 | ||
Municipal bonds — available-for-sale | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Proceeds from available for sale municipal bonds | 2,000 | 10,400 | 26,700 |
Realized loss | $ 100 | $ 100 | |
Realized gain | $ 100 |
Fair Value Measurements - Marke
Fair Value Measurements - Marketable Securities and Deferred Compensation Fund Investments (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | $ 93,131 | $ 95,200 |
Deferred compensation funding, at fair value | 40,812 | 33,493 |
Prepaid expenses and other assets | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 1,500 | 1,600 |
Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 40,306 | 32,691 |
Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 2,007 | 2,420 |
Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 42,313 | 35,111 |
Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 42,313 | 35,111 |
Municipal bonds — available-for-sale | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 93,131 | 95,200 |
Municipal bonds — available-for-sale | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
Municipal bonds — available-for-sale | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 93,131 | 95,200 |
Municipal bonds — available-for-sale | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 0 | 0 |
Municipal bonds — available-for-sale | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 93,131 | 95,200 |
Municipal bonds — available-for-sale | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable securities | 93,131 | 95,200 |
Money Market | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Money Market | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 2,007 | 2,420 |
Money Market | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Money Market | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 2,007 | 2,420 |
Money Market | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 2,007 | 2,420 |
Commodities | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 298 | 170 |
Commodities | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Commodities | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Commodities | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 298 | 170 |
Commodities | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 298 | 170 |
Fixed Income | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 4,254 | 3,571 |
Fixed Income | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Fixed Income | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Fixed Income | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 4,254 | 3,571 |
Fixed Income | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 4,254 | 3,571 |
International | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 4,621 | 4,093 |
International | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
International | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
International | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 4,621 | 4,093 |
International | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 4,621 | 4,093 |
Large Cap Blend | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 5,053 | 1,210 |
Large Cap Blend | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Large Cap Blend | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Large Cap Blend | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 5,053 | 1,210 |
Large Cap Blend | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 5,053 | 1,210 |
Large Cap Growth | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 13,886 | 11,064 |
Large Cap Growth | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Large Cap Growth | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Large Cap Growth | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 13,886 | 11,064 |
Large Cap Growth | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 13,886 | 11,064 |
Large Cap Value | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 5,964 | 6,133 |
Large Cap Value | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Large Cap Value | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Large Cap Value | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 5,964 | 6,133 |
Large Cap Value | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 5,964 | 6,133 |
Mid Cap Blend | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 3,192 | 2,667 |
Mid Cap Blend | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Mid Cap Blend | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Mid Cap Blend | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 3,192 | 2,667 |
Mid Cap Blend | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 3,192 | 2,667 |
Real Estate | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 374 | 359 |
Real Estate | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Real Estate | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Real Estate | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 374 | 359 |
Real Estate | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 374 | 359 |
Small Cap Blend | Quoted Prices in Active Markets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 2,664 | 3,424 |
Small Cap Blend | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Small Cap Blend | Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 0 | 0 |
Small Cap Blend | Carrying Amount | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | 2,664 | 3,424 |
Small Cap Blend | Total Fair Value | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Deferred compensation funding, at fair value | $ 2,664 | $ 3,424 |
Fair Value Measurements - Mar_2
Fair Value Measurements - Marketable Debt Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items] | ||
Amortized Cost | $ 95,466 | $ 99,601 |
Gross Unrealized Gains | 387 | 229 |
Gross Unrealized Losses | (2,722) | (4,630) |
Estimated Fair Value | 93,131 | 95,200 |
Impairments | 0 | 0 |
Municipal bonds — available-for-sale | ||
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items] | ||
Amortized Cost | 95,466 | 99,601 |
Gross Unrealized Gains | 387 | 229 |
Gross Unrealized Losses | (2,722) | (4,630) |
Estimated Fair Value | 93,131 | 95,200 |
Impairments | $ 0 | $ 0 |
Fair Value Measurements - Contr
Fair Value Measurements - Contractual Maturities of Debt Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Fair Value Disclosures [Abstract] | ||
Maturing in one year or less | $ 6,324 | $ 2,798 |
Maturing in second year through fifth year | 34,939 | 35,068 |
Maturing in sixth year through tenth year | 39,309 | 38,575 |
Maturing after ten years | 12,559 | 18,759 |
Total debt securities | $ 93,131 | $ 95,200 |
Share-Based Compensation - Sche
Share-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total pre-tax share-based compensation expense charged against income | $ 8,985 | $ 9,214 | $ 8,827 |
Total recognized tax deficiency related to share-based compensation | (773) | (783) | (217) |
Selling, general & administrative expense | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total pre-tax share-based compensation expense charged against income | 8,942 | 9,160 | 8,767 |
Costs of services provided | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total pre-tax share-based compensation expense charged against income | 43 | 54 | 60 |
Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total pre-tax share-based compensation expense charged against income | 969 | 1,253 | 1,832 |
Restricted stock, restricted stock units and deferred stock units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total pre-tax share-based compensation expense charged against income | 6,657 | 6,972 | 6,367 |
Performance stock units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total pre-tax share-based compensation expense charged against income | 1,210 | 819 | 401 |
Employee Stock Purchase Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total pre-tax share-based compensation expense charged against income | $ 149 | $ 170 | $ 227 |
Share-Based Compensation - Addi
Share-Based Compensation - Additional Information (Details) | 12 Months Ended | ||||
May 30, 2023 shares | Feb. 24, 2023 shares | Dec. 31, 2023 USD ($) participant $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Unrecognized compensation cost | $ | $ 16,500,000 | $ 15,800,000 | |||
Period of expense of unrecognized compensation cost | 2 years 9 months 18 days | 2 years 9 months 18 days | |||
Weighted average grant-date fair value of stock options granted (in dollars per share) | $ / shares | $ 6.53 | $ 4.06 | $ 7.01 | ||
Aggregate intrinsic value of stock options exercised | $ | $ 0 | $ 100,000 | $ 700,000 | ||
Fair value of options vested | $ | $ 1,300,000 | $ 1,800,000 | $ 2,100,000 | ||
Weighted average grant-date fair value of restricted stock units granted (in dollars per share) | $ / shares | $ 13.72 | $ 18.06 | $ 28.53 | ||
SERP | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Percentage of earned income on a pre-tax basis, deferred | 25% | ||||
Percentage of match participants' deferrals | 25% | ||||
Percentage of deferral in the form of common stock | 15% | ||||
Full vest in matching contribution | 3 years | ||||
Shares authorized for issuance (in shares) | 1,000,000 | ||||
Common stock reserved for future issuance (in shares) | 200,000 | ||||
Stock options vested and outstanding (in shares) | 300,000 | ||||
Restricted Stock Units | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Period of expense of unrecognized compensation cost | 3 years 1 month 6 days | ||||
Restricted stock granted (in shares) | 536,000 | 400,000 | 300,000 | ||
Weighted average grant-date fair value of restricted stock units granted (in dollars per share) | $ / shares | $ 13.72 | $ 18.06 | $ 28.53 | ||
Performance stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Unrecognized compensation cost | $ | $ 1,300,000 | ||||
Period of expense of unrecognized compensation cost | 1 year 4 months 24 days | ||||
Restricted stock granted (in shares) | 80,000 | 80,000 | |||
Weighted average grant-date fair value of restricted stock units granted (in dollars per share) | $ / shares | $ 16.20 | ||||
Vesting period | 3 years | ||||
Deferred stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Payout period | 5 years | ||||
Deferred stock units | Non employee director | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Unrecognized compensation cost | $ | $ 100,000 | ||||
Period of expense of unrecognized compensation cost | 4 months 24 days | ||||
Restricted stock granted (in shares) | 23,000 | ||||
Vesting period | 1 year | ||||
Number of participants electing to receive shares | participant | 2 | ||||
ESPP | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Shares available for future grant (in shares) | 1,800,000 | ||||
Average weekly hours of work | 20 hours | ||||
Requisite service period for plan participation eligibility | 2 years | ||||
Stock options authorized to issue to employees (in shares) | 4,100,000 | ||||
Annual earnings withheld to purchase common stock | $ | $ 21,250 | ||||
Percent of IRS limitation | 85% | ||||
Maximum fair value of common stock purchased | $ | $ 25,000 | ||||
ESPP purchase price of common stock, percent of market price | 85% | ||||
ESPP purchase price of common stock, percent of market price offering period | 85% | ||||
2020 Omnibus Incentive Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Increase in shares authorized under plan (in shares) | 2,500,000 | ||||
Common stock reserved for future issuance (in shares) | 7,000,000 | ||||
Shares available for future grant (in shares) | 3,200,000 | ||||
Maximum term of grants | 10 years |
Share-Based Compensation - Sc_2
Share-Based Compensation - Schedule of Stock Options Outstanding (Details) shares in Thousands | 12 Months Ended |
Dec. 31, 2023 $ / shares shares | |
Number of Shares | |
Beginning of period (in shares) | shares | 2,375 |
Granted (in shares) | shares | 207 |
Exercised (in shares) | shares | 0 |
Forfeited (in shares) | shares | 0 |
Expired (in shares) | shares | (144) |
End of period (in shares) | shares | 2,438 |
Weighted Average Exercise Price | |
Beginning of period (in dollars per share) | $ / shares | $ 31.56 |
Granted (in dollars per share) | $ / shares | 13.72 |
Exercised (in dollars per share) | $ / shares | 0 |
Forfeited (in dollars per share) | $ / shares | 0 |
Expired (in dollars per share) | $ / shares | 24.99 |
End of period (in dollars per share) | $ / shares | $ 30.43 |
Share-Based Compensation - Assu
Share-Based Compensation - Assumptions for Fair Value of Options Granted (Details) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-Based Payment Arrangement [Abstract] | |||
Risk-free interest rate | 4% | 1.50% | 0.60% |
Weighted average expected life | 6 years 10 months 24 days | 6 years 8 months 12 days | 6 years 7 months 6 days |
Expected volatility | 39.50% | 36.60% | 34.70% |
Dividend yield | 0% | 4.60% | 2.90% |
Share-Based Compensation - Sc_3
Share-Based Compensation - Schedule of Information About Stock Awards (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) $ / shares shares | |
Outstanding: | |
Aggregate intrinsic value | $ 0 |
Weighted average remaining contractual life | 4 years 6 months |
Exercisable: | |
Number of options (in shares) | shares | 1,702 |
Weighted average exercise price (in dollars per share) | $ / shares | $ 34.72 |
Aggregate intrinsic value | $ 0 |
Weighted average remaining contractual life | 2 years 7 months 6 days |
Share-Based Compensation - Sc_4
Share-Based Compensation - Schedule of Restricted Stock Units (Details) - $ / shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Weighted Average Grant Date Fair Value | |||
Granted (in dollars per share) | $ 13.72 | $ 18.06 | $ 28.53 |
Restricted Stock Units | |||
Number | |||
Beginning balance (in shares) | 825 | ||
Granted (in shares) | 536 | 400 | 300 |
Vested (in shares) | (237) | ||
Forfeited (in shares) | (22) | ||
Ending balance (in shares) | 1,102 | 825 | |
Weighted Average Grant Date Fair Value | |||
Beginning balance (in dollars per share) | $ 24.37 | ||
Granted (in dollars per share) | 13.72 | $ 18.06 | $ 28.53 |
Vested (in dollars per share) | 27.82 | ||
Forfeited (in dollars per share) | 18.76 | ||
Ending balance (in dollars per share) | $ 18.57 | $ 24.37 |
Share-Based Compensation - Weig
Share-Based Compensation - Weighted Average Remaining Grant-Date and Total Fair Values (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-Based Payment Arrangement [Abstract] | |||
Weighted average grant-date fair value of restricted stock units granted (in dollars per share) | $ 13.72 | $ 18.06 | $ 28.53 |
Total fair value of restricted stock units and restricted shares vested | $ 2,991 | $ 3,307 | $ 4,185 |
Share-Based Compensation - Sc_5
Share-Based Compensation - Schedule of Outstanding Performance Stock Units (Details) - $ / shares | 12 Months Ended | |||
Feb. 24, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Weighted Average Grant Date Fair Value | ||||
Granted (in dollars per share) | $ 13.72 | $ 18.06 | $ 28.53 | |
Performance stock units | ||||
Number | ||||
Beginning balance (in shares) | 95,000 | |||
Granted (in shares) | 80,000 | 80,000 | ||
Vested (in shares) | 0 | |||
Forfeited (in shares) | 0 | |||
Ending balance (in shares) | 175,000 | 95,000 | ||
Weighted Average Grant Date Fair Value | ||||
Beginning balance (in dollars per share) | $ 26.01 | |||
Granted (in dollars per share) | 16.20 | |||
Vested (in dollars per share) | 0 | |||
Forfeited (in dollars per share) | 0 | |||
Ending balance (in dollars per share) | $ 21.52 | $ 26.01 |
Share Based Compensation - Sche
Share Based Compensation - Schedule of ESPP Annual Offerings (Details) - ESPP - $ / shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Common shares purchased (in shares) | 95 | 95 | 85 |
Per common share purchase price (in dollars per share) | $ 8.81 | $ 10.20 | $ 15.12 |
Share-Based Compensation - As_2
Share-Based Compensation - Assumptions For Employee Stock Purchase Plan (Details) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Risk-free interest rate | 4% | 1.50% | 0.60% |
Weighted average expected life (years) | 6 years 10 months 24 days | 6 years 8 months 12 days | 6 years 7 months 6 days |
Expected volatility | 39.50% | 36.60% | 34.70% |
Dividend yield | 0% | 4.60% | 2.90% |
ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Risk-free interest rate | 4.80% | 0.40% | |
Weighted average expected life (years) | 1 year | 1 year | |
Expected volatility | 42.90% | 36.90% | |
Dividend yield | 7.10% | 4.70% |
Share-Based Compensation - Defe
Share-Based Compensation - Deferred Compensation Plan (Details) - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
SERP expense | $ 8,985 | $ 9,214 | $ 8,827 |
SERP | |||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | |||
SERP expense | $ 533 | $ 486 | $ 531 |
Treasury shares issued to fund SERP expense (in shares) | 50 | 40 | 30 |
Year end SERP trust account balance | $ 42,313 | $ 35,111 | $ 59,086 |
Unrealized gain (loss) recorded in SERP liability account | $ 6,684 | $ (9,178) | $ 6,676 |
Income Taxes - Schedule of Prov
Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Current: | |||
Federal | $ 13,728 | $ 3,022 | $ 9,120 |
State | 5,762 | 2,381 | 3,766 |
Total | 19,490 | 5,403 | 12,886 |
Deferred: | |||
Federal | (4,183) | 4,163 | 3,127 |
State | (637) | 744 | 956 |
Total | (4,820) | 4,907 | 4,083 |
Tax provision | $ 14,670 | $ 10,310 | $ 16,969 |
Income Taxes - Significant Comp
Income Taxes - Significant Components of Federal and State Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets: | ||
Allowance for doubtful accounts | $ 22,788 | $ 18,139 |
Deferred compensation | 9,048 | 8,686 |
Accrued insurance claims | 5,580 | 5,609 |
Non-deductible reserves | 169 | 256 |
Lease liabilities | 4,765 | 5,709 |
Share based compensation | 2,988 | 2,142 |
Other | 2,418 | 2,848 |
Deferred tax assets | 47,756 | 43,389 |
Deferred tax liabilities: | ||
Expensing of housekeeping supplies | (2,351) | (2,510) |
Amortization of goodwill and intangibles | (3,000) | (2,389) |
Depreciation of property and equipment | (1,688) | (1,769) |
Lease right-of-use assets | (4,571) | (5,482) |
Other | (920) | (399) |
Deferred tax liabilities | (12,530) | (12,549) |
Net deferred tax assets | $ 35,226 | $ 30,840 |
Income Taxes - Reconciliation o
Income Taxes - Reconciliation of the Provision for Income Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Effective Income Tax Rate Reconciliation, Amount [Abstract] | |||
Income tax expense computed at statutory rate | $ 11,182 | $ 9,356 | $ 13,758 |
Increases (decreases) resulting from: | |||
State income taxes, net of federal tax benefit | 4,153 | 2,594 | 4,165 |
Federal jobs credits | (2,014) | (2,571) | (3,177) |
Tax exempt interest | (348) | (308) | (324) |
Share-based compensation | 1,610 | 1,250 | 1,072 |
Fines and penalties | 55 | 4 | 1,294 |
Other, net | 32 | (15) | 181 |
Tax provision | $ 14,670 | $ 10,310 | $ 16,969 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
Change in liability for unrecognized tax benefit | $ 0 | $ 0 |
Segment Information - Schedule
Segment Information - Schedule of Segment Information (Details) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 USD ($) segment | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Segment Reporting [Abstract] | |||
Number of reportable segments | segment | 2 | ||
Segment Reporting Information [Line Items] | |||
Revenues | $ 1,671,389 | $ 1,690,176 | $ 1,641,959 |
Income before income taxes | 53,056 | 44,553 | 65,512 |
Depreciation and amortization | 14,344 | 15,316 | 14,667 |
Total assets | 790,652 | 720,836 | 779,889 |
Capital expenditures | 5,406 | 5,210 | 5,687 |
Genesis | Consolidated revenues | Significant Customers | |||
Segment Reporting Information [Line Items] | |||
Revenues | $ 181,400 | $ 169,100 | $ 177,100 |
Contribution percent | 10.90% | 10% | 10.80% |
Housekeeping | |||
Segment Reporting Information [Line Items] | |||
Revenues | $ 766,700 | $ 795,700 | $ 821,300 |
Dietary | |||
Segment Reporting Information [Line Items] | |||
Revenues | 904,700 | 894,500 | 820,600 |
Operating Segments | Housekeeping | |||
Segment Reporting Information [Line Items] | |||
Revenues | 766,651 | 795,687 | 821,329 |
Income before income taxes | 61,311 | 73,096 | 79,380 |
Depreciation and amortization | 4,380 | 5,491 | 5,399 |
Total assets | 253,729 | 250,444 | 225,531 |
Capital expenditures | 4,684 | 4,412 | 5,005 |
Operating Segments | Dietary | |||
Segment Reporting Information [Line Items] | |||
Revenues | 904,738 | 894,489 | 820,630 |
Income before income taxes | 43,547 | 29,065 | 45,758 |
Depreciation and amortization | 3,001 | 3,075 | 2,611 |
Total assets | 291,550 | 263,126 | 221,911 |
Capital expenditures | 494 | 499 | 451 |
Corporate, Non-Segment | |||
Segment Reporting Information [Line Items] | |||
Income before income taxes | (51,802) | (57,608) | (59,626) |
Depreciation and amortization | 6,963 | 6,750 | 6,657 |
Total assets | 245,373 | 207,266 | 332,447 |
Capital expenditures | $ 228 | $ 299 | $ 231 |
Earnings Per Common Share - Sch
Earnings Per Common Share - Schedule of Weighted Average Number of Shares (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Numerator for basic and diluted earnings per share: | |||
Net income | $ 38,386 | $ 34,243 | $ 48,543 |
Denominator: | |||
Weighted average number of common shares outstanding - basic (in shares) | 74,288 | 74,336 | 74,816 |
Effect of dilutive securities (in shares) | 52 | 15 | 146 |
Weighted average number of common shares outstanding - diluted (in shares) | 74,340 | 74,351 | 74,962 |
Basic earnings per share (in dollars per share) | $ 0.52 | $ 0.46 | $ 0.65 |
Diluted earnings per share (in dollars per share) | $ 0.52 | $ 0.46 | $ 0.65 |
Earnings Per Common Share - S_2
Earnings Per Common Share - Schedule Anti-dilutive Outstanding Equity Awards Under Share Based Compensation Plans (Details) - shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |||
Anti-dilutive equity awards (in shares) | 3,228 | 3,203 | 1,980 |
Other Contingencies (Details)
Other Contingencies (Details) | 12 Months Ended | ||
Nov. 22, 2022 USD ($) | Dec. 31, 2023 USD ($) covenant | Dec. 31, 2022 USD ($) | |
Short-term Debt [Line Items] | |||
Bank line of credit | $ 300,000,000 | ||
Borrowings under line of credit | $ 25,000,000 | $ 25,000,000 | |
Financial covenants | covenant | 2 | ||
Line of Credit | Revolving Credit Facility | Unsecured Revolving Loan Facility | |||
Short-term Debt [Line Items] | |||
Bank line of credit | $ 300,000,000 | ||
Unsecured revolving loan facility expiration period | 5 years | ||
Accordion feature, higher borrowing capacity option | $ 500,000,000 | ||
Standby letters of credit | |||
Short-term Debt [Line Items] | |||
Irrevocable standby letter of credit, outstanding | $ 85,900,000 | ||
Reduction of bank line of credit | 85,900,000 | ||
Amount available under line of credit | $ 189,100,000 | ||
SOFR | |||
Short-term Debt [Line Items] | |||
Basis spread on variable rate | 1.65% |
Other Employee Benefit Plans (D
Other Employee Benefit Plans (Details) | 12 Months Ended |
Dec. 31, 2023 | |
Retirement Benefits [Abstract] | |
Maximum percentage of employee contribution | 15% |
Accrued Insurance Claims (Detai
Accrued Insurance Claims (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Payables and Accruals [Abstract] | ||
Percent of liabilities | 25.30% | 29.30% |
Favorable adjustment in self-insurance reserves | $ (12.5) |
Treasury Stock (Details)
Treasury Stock (Details) - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Feb. 14, 2023 | |
Equity [Abstract] | |||
Number of shares authorized to be repurchased up to (in shares) | 7.5 | ||
Purchase of treasury stock (in shares) | 1 | 0 | |
Total cost inclusive of transaction costs | $ 11.1 |
Schedule II - Valuation and Q_2
Schedule II - Valuation and Qualifying Accounts and Reserves (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Beginning Balance | $ 73,464 | $ 65,584 | $ 67,801 |
Charged to Costs and Expenses | 35,604 | 31,969 | 10,483 |
Deductions | 17,369 | 24,088 | 12,700 |
Ending Balance | $ 91,699 | $ 73,464 | $ 65,584 |